US20020106338A1 - Galenical formulation - Google Patents
Galenical formulation Download PDFInfo
- Publication number
- US20020106338A1 US20020106338A1 US09/987,439 US98743901A US2002106338A1 US 20020106338 A1 US20020106338 A1 US 20020106338A1 US 98743901 A US98743901 A US 98743901A US 2002106338 A1 US2002106338 A1 US 2002106338A1
- Authority
- US
- United States
- Prior art keywords
- compound according
- cosmetic
- group
- formulation
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 98
- 238000009472 formulation Methods 0.000 title claims description 35
- 150000001875 compounds Chemical class 0.000 claims abstract description 88
- 239000004904 UV filter Substances 0.000 claims abstract description 25
- 239000002537 cosmetic Substances 0.000 claims description 42
- 238000002360 preparation method Methods 0.000 claims description 34
- 239000003963 antioxidant agent Substances 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 230000032683 aging Effects 0.000 claims description 11
- 230000005855 radiation Effects 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 230000003078 antioxidant effect Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 230000002633 protecting effect Effects 0.000 claims description 7
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical compound C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 230000036542 oxidative stress Effects 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 3
- 125000005019 carboxyalkenyl group Chemical group 0.000 claims description 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- 125000005429 oxyalkyl group Chemical group 0.000 claims 1
- 230000009931 harmful effect Effects 0.000 abstract description 6
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 239000012071 phase Substances 0.000 description 66
- -1 flavone glycosides Chemical class 0.000 description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 46
- 239000000126 substance Substances 0.000 description 41
- 210000003491 skin Anatomy 0.000 description 39
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 38
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- 239000003755 preservative agent Substances 0.000 description 24
- 235000014113 dietary fatty acids Nutrition 0.000 description 21
- 239000000194 fatty acid Substances 0.000 description 21
- 229930195729 fatty acid Natural products 0.000 description 21
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 20
- 239000003921 oil Substances 0.000 description 20
- 235000019198 oils Nutrition 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- 238000003756 stirring Methods 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 150000003254 radicals Chemical class 0.000 description 16
- 0 [1*]C.[2*]C.[3*]C.[4*]C.[5*]C1C(=[Y])C2=CC=CC=C2*[C@@H]1C1=CC=CC=C1 Chemical compound [1*]C.[2*]C.[3*]C.[4*]C.[5*]C1C(=[Y])C2=CC=CC=C2*[C@@H]1C1=CC=CC=C1 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 235000006708 antioxidants Nutrition 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 235000011187 glycerol Nutrition 0.000 description 13
- 239000006210 lotion Substances 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- 239000000470 constituent Substances 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 11
- 150000004665 fatty acids Chemical class 0.000 description 11
- 230000002335 preservative effect Effects 0.000 description 11
- 230000000475 sunscreen effect Effects 0.000 description 11
- 239000000516 sunscreening agent Substances 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 10
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 10
- 229960003415 propylparaben Drugs 0.000 description 10
- 239000001993 wax Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 9
- 229930003935 flavonoid Natural products 0.000 description 9
- 150000002215 flavonoids Chemical class 0.000 description 9
- 235000017173 flavonoids Nutrition 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 229940008099 dimethicone Drugs 0.000 description 8
- 239000004205 dimethyl polysiloxane Substances 0.000 description 8
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 8
- 238000000265 homogenisation Methods 0.000 description 8
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 8
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 8
- 235000013772 propylene glycol Nutrition 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- 239000004166 Lanolin Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 235000019388 lanolin Nutrition 0.000 description 7
- 229940039717 lanolin Drugs 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 7
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 6
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 6
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 6
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 235000015165 citric acid Nutrition 0.000 description 6
- 229960004106 citric acid Drugs 0.000 description 6
- 229940125782 compound 2 Drugs 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000005875 quercetin Nutrition 0.000 description 6
- 229960001285 quercetin Drugs 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000011732 tocopherol Substances 0.000 description 6
- 229930003799 tocopherol Natural products 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 229940123457 Free radical scavenger Drugs 0.000 description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- HEAHZSUCFKFERC-IWGRKNQJSA-N [(2e)-2-[[4-[(e)-[7,7-dimethyl-3-oxo-4-(sulfomethyl)-2-bicyclo[2.2.1]heptanylidene]methyl]phenyl]methylidene]-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical group CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)\C2=C\C(C=C1)=CC=C1\C=C/1C(=O)C2(CS(O)(=O)=O)CCC\1C2(C)C HEAHZSUCFKFERC-IWGRKNQJSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 5
- 150000002191 fatty alcohols Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002304 perfume Substances 0.000 description 5
- 239000002516 radical scavenger Substances 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 4
- 241001135917 Vitellaria paradoxa Species 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 235000013871 bee wax Nutrition 0.000 description 4
- 239000012166 beeswax Substances 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 229960000541 cetyl alcohol Drugs 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 229940057910 shea butter Drugs 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229960001295 tocopherol Drugs 0.000 description 4
- 235000010384 tocopherol Nutrition 0.000 description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 3
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 3
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 229940022663 acetate Drugs 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- SAVROPQJUYSBDD-UHFFFAOYSA-N formyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)=CO SAVROPQJUYSBDD-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 235000019172 retinyl palmitate Nutrition 0.000 description 3
- 239000011769 retinyl palmitate Substances 0.000 description 3
- 229940108325 retinyl palmitate Drugs 0.000 description 3
- 230000037380 skin damage Effects 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titanium dioxide Inorganic materials O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- 229940042585 tocopherol acetate Drugs 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 229910052721 tungsten Inorganic materials 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 235000014692 zinc oxide Nutrition 0.000 description 3
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 2
- UHGGERUQGSJHKR-VCDGYCQFSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;octadecanoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCCCCCCCCCCCC(O)=O UHGGERUQGSJHKR-VCDGYCQFSA-N 0.000 description 2
- OIQXFRANQVWXJF-QBFSEMIESA-N (2z)-2-benzylidene-4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical class CC1(C)C2CCC1(C)C(=O)\C2=C/C1=CC=CC=C1 OIQXFRANQVWXJF-QBFSEMIESA-N 0.000 description 2
- PAEMERHSTIDLSE-VEIQOZLZSA-N (3r,4s,5s,6r)-2-hexadecoxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound CCCCCCCCCCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PAEMERHSTIDLSE-VEIQOZLZSA-N 0.000 description 2
- AALXZHPCKJILAZ-UHFFFAOYSA-N (4-propan-2-ylphenyl)methyl 2-hydroxybenzoate Chemical compound C1=CC(C(C)C)=CC=C1COC(=O)C1=CC=CC=C1O AALXZHPCKJILAZ-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 2
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-SZSCBOSDSA-N 2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one Chemical compound OC[C@H](O)C1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-SZSCBOSDSA-N 0.000 description 2
- FHCBGGAPSRVQCN-UHFFFAOYSA-N 2-[1-[1-(2-hexyldodecoxy)propan-2-yloxy]propan-2-yloxy]ethyl acetate Chemical compound CCCCCCCCCCC(CCCCCC)COCC(C)OCC(C)OCCOC(C)=O FHCBGGAPSRVQCN-UHFFFAOYSA-N 0.000 description 2
- VQRYFZAADGPXBH-UHFFFAOYSA-N 2-phenyl-3h-benzimidazole-5-sulfonyl chloride Chemical compound N1C2=CC(S(=O)(=O)Cl)=CC=C2N=C1C1=CC=CC=C1 VQRYFZAADGPXBH-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010087806 Carnosine Proteins 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- 239000011703 D-panthenol Substances 0.000 description 2
- 235000004866 D-panthenol Nutrition 0.000 description 2
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 2
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 230000037338 UVA radiation Effects 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- IWTYTFSSTWXZFU-QPJJXVBHSA-N [(e)-3-chloroprop-1-enyl]benzene Chemical compound ClC\C=C\C1=CC=CC=C1 IWTYTFSSTWXZFU-QPJJXVBHSA-N 0.000 description 2
- SZAMSYKZCSDVBH-CLFAGFIQSA-N [(z)-octadec-9-enyl] (z)-docos-13-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(=O)OCCCCCCCC\C=C/CCCCCCCC SZAMSYKZCSDVBH-CLFAGFIQSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 2
- UBNYRXMKIIGMKK-RMKNXTFCSA-N amiloxate Chemical compound COC1=CC=C(\C=C\C(=O)OCCC(C)C)C=C1 UBNYRXMKIIGMKK-RMKNXTFCSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 235000015197 apple juice Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 229940036350 bisabolol Drugs 0.000 description 2
- 238000004061 bleaching Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 2
- 229940044199 carnosine Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 2
- 229960003949 dexpanthenol Drugs 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- HJQLXIPVQPEJRY-UHFFFAOYSA-N hexadecyl 3,5,5-trimethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CC(C)CC(C)(C)C HJQLXIPVQPEJRY-UHFFFAOYSA-N 0.000 description 2
- 229940100463 hexyl laurate Drugs 0.000 description 2
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 2
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 2
- 235000009498 luteolin Nutrition 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229960001679 octinoxate Drugs 0.000 description 2
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical compound C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 2
- 229940120511 oleyl erucate Drugs 0.000 description 2
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 229940098760 steareth-2 Drugs 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 2
- 230000037072 sun protection Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 235000010215 titanium dioxide Nutrition 0.000 description 2
- 125000002640 tocopherol group Chemical class 0.000 description 2
- 235000019149 tocopherols Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 2
- 239000011653 vitamin D2 Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- PDHSAQOQVUXZGQ-JKSUJKDBSA-N (2r,3s)-2-(3,4-dihydroxyphenyl)-3-methoxy-3,4-dihydro-2h-chromene-5,7-diol Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2OC)=CC=C(O)C(O)=C1 PDHSAQOQVUXZGQ-JKSUJKDBSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- LNJRMYPOKFOJBQ-UHFFFAOYSA-N 1-(4-tert-butyl-4-methoxycyclohexa-1,5-dien-1-yl)ethanone Chemical compound COC1(C(C)(C)C)CC=C(C(C)=O)C=C1 LNJRMYPOKFOJBQ-UHFFFAOYSA-N 0.000 description 1
- JZTVUOGGDMJFLX-UHFFFAOYSA-N 1-(4-tert-butylphenyl)-3-(4-chlorophenyl)propane-1,3-dione Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CC(=O)C1=CC=C(Cl)C=C1 JZTVUOGGDMJFLX-UHFFFAOYSA-N 0.000 description 1
- YHRPNAWFNBZECU-NSCUHMNNSA-N 1-[(e)-3-chloroprop-1-enyl]-4-methoxybenzene Chemical compound COC1=CC=C(\C=C\CCl)C=C1 YHRPNAWFNBZECU-NSCUHMNNSA-N 0.000 description 1
- LALVCWMSKLEQMK-UHFFFAOYSA-N 1-phenyl-3-(4-propan-2-ylphenyl)propane-1,3-dione Chemical compound C1=CC(C(C)C)=CC=C1C(=O)CC(=O)C1=CC=CC=C1 LALVCWMSKLEQMK-UHFFFAOYSA-N 0.000 description 1
- ATVKWBAMWLLBPS-UHFFFAOYSA-N 1h-benzimidazole-4,6-disulfonic acid Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2N=CNC2=C1 ATVKWBAMWLLBPS-UHFFFAOYSA-N 0.000 description 1
- WQXNXVUDBPYKBA-UHFFFAOYSA-N 2-Methyl-4-carboxy-3,4,5,6-tetrahydropyrimidine Chemical compound CC1=NCCC(C(O)=O)N1 WQXNXVUDBPYKBA-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 description 1
- ODJQKYXPKWQWNK-UHFFFAOYSA-N 3,3'-Thiobispropanoic acid Chemical compound OC(=O)CCSCCC(O)=O ODJQKYXPKWQWNK-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- MCLMZMISZCYBBG-UHFFFAOYSA-N 3-ethylheptanoic acid Chemical compound CCCCC(CC)CC(O)=O MCLMZMISZCYBBG-UHFFFAOYSA-N 0.000 description 1
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 1
- GWXXFGWOWOJEEX-UHFFFAOYSA-N 4,4,4-trihydroxy-1-phenylbutan-1-one Chemical compound OC(CCC(=O)C1=CC=CC=C1)(O)O GWXXFGWOWOJEEX-UHFFFAOYSA-N 0.000 description 1
- KKJKXQYVUVWWJP-UHFFFAOYSA-N 4-[(4,7,7-trimethyl-3-oxo-2-bicyclo[2.2.1]heptanylidene)methyl]benzenesulfonic acid Chemical compound CC1(C)C2CCC1(C)C(=O)C2=CC1=CC=C(S(O)(=O)=O)C=C1 KKJKXQYVUVWWJP-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical class CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 241001237961 Amanita rubescens Species 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 108010085443 Anserine Proteins 0.000 description 1
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 1
- GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 description 1
- RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 description 1
- SZHVIMKPTLPBMU-UHFFFAOYSA-N CC1(C)OC2=C(C=C(C3=C(O)C(=O)C4=C(O)C=C(O)C=C4O3)C=C2)O1.O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC2=C1C(O)=CC(O)=C2 Chemical compound CC1(C)OC2=C(C=C(C3=C(O)C(=O)C4=C(O)C=C(O)C=C4O3)C=C2)O1.O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC2=C1C(O)=CC(O)=C2 SZHVIMKPTLPBMU-UHFFFAOYSA-N 0.000 description 1
- AYDSVKWZNUHGPS-UHFFFAOYSA-N CCCCCC(CC)OC(=O)C1=CC=C(N(C)C)C=C1.CN(C)C1=CC=C(C(=O)I)C=C1 Chemical compound CCCCCC(CC)OC(=O)C1=CC=C(N(C)C)C=C1.CN(C)C1=CC=C(C(=O)I)C=C1 AYDSVKWZNUHGPS-UHFFFAOYSA-N 0.000 description 1
- DMDMAXNISWZLPA-ZQSAYXGUSA-N COC1=CC=C(/C=C/C(=O)Cl)C=C1.COC1=CC=C(/C=C/C(=O)OC2=C(OC(=O)/C=C/C3=CC=C(OC)C=C3)C=C(C3=CC(=O)C4=C(O)C=C(OC(=O)/C=C/C5=CC=C(C=O)C=C5)C=C4O3)C=C2)C=C1.O=C1C=C(C2=CC(O)=C(O)C=C2)OC2=CC(O)=CC(O)=C12 Chemical compound COC1=CC=C(/C=C/C(=O)Cl)C=C1.COC1=CC=C(/C=C/C(=O)OC2=C(OC(=O)/C=C/C3=CC=C(OC)C=C3)C=C(C3=CC(=O)C4=C(O)C=C(OC(=O)/C=C/C5=CC=C(C=O)C=C5)C=C4O3)C=C2)C=C1.O=C1C=C(C2=CC(O)=C(O)C=C2)OC2=CC(O)=CC(O)=C12 DMDMAXNISWZLPA-ZQSAYXGUSA-N 0.000 description 1
- FQPVCGIYFFEIMY-DJNOCYBKSA-N COC1=CC=C(/C=C/C(=O)Cl)C=C1.COC1=CC=C(/C=C/C(=O)OCCOC2=CC(O)=C3C(=O)C=C(C4=CC(OCCOC(=O)/C=C/C5=CC=C(OC)C=C5)=C(OCCOC(=O)/C=C/C5=CC=C(OC)C=C5)C=C4)CC3=C2)C=C1.O=C1C=C(C2=CC(OCCO)=C(OCCO)C=C2)OC2=CC(OCCO)=CC(O)=C12 Chemical compound COC1=CC=C(/C=C/C(=O)Cl)C=C1.COC1=CC=C(/C=C/C(=O)OCCOC2=CC(O)=C3C(=O)C=C(C4=CC(OCCOC(=O)/C=C/C5=CC=C(OC)C=C5)=C(OCCOC(=O)/C=C/C5=CC=C(OC)C=C5)C=C4)CC3=C2)C=C1.O=C1C=C(C2=CC(OCCO)=C(OCCO)C=C2)OC2=CC(OCCO)=CC(O)=C12 FQPVCGIYFFEIMY-DJNOCYBKSA-N 0.000 description 1
- UZWFUSZJBFAXBC-UHFFFAOYSA-N CS(=O)(=O)C1=CC=C2N=C(C3=CC=CC=C3)NC2=C1.O=C1C(O)=C(C2=CC(OCC3=CC=CC=C3)=C(OCC3=CC=CC=C3)C=C2)OC2=CC(OCC3=CC=CC=C3)=CC(O)=C12.O=S(=O)(Cl)C1=CC=C2N=C(C3=CC=CC=C3)NC2=C1.O=S(=O)(O)C1=CC=C2N=C(C3=CC=CC=C3)NC2=C1 Chemical compound CS(=O)(=O)C1=CC=C2N=C(C3=CC=CC=C3)NC2=C1.O=C1C(O)=C(C2=CC(OCC3=CC=CC=C3)=C(OCC3=CC=CC=C3)C=C2)OC2=CC(OCC3=CC=CC=C3)=CC(O)=C12.O=S(=O)(Cl)C1=CC=C2N=C(C3=CC=CC=C3)NC2=C1.O=S(=O)(O)C1=CC=C2N=C(C3=CC=CC=C3)NC2=C1 UZWFUSZJBFAXBC-UHFFFAOYSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 102000006378 Catechol O-methyltransferase Human genes 0.000 description 1
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- LAAPRQODJPXAHC-UHFFFAOYSA-N Coniferyl benzoate Natural products C1=C(O)C(OC)=CC(C=CCOC(=O)C=2C=CC=CC=2)=C1 LAAPRQODJPXAHC-UHFFFAOYSA-N 0.000 description 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
- 108050008072 Cytochrome c oxidase subunit IV Proteins 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- GHKOFFNLGXMVNJ-UHFFFAOYSA-N Didodecyl thiobispropanoate Chemical compound CCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCC GHKOFFNLGXMVNJ-UHFFFAOYSA-N 0.000 description 1
- 239000003508 Dilauryl thiodipropionate Substances 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000002656 Distearyl thiodipropionate Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100037095 Histidine decarboxylase Human genes 0.000 description 1
- 108010014095 Histidine decarboxylase Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- SWFOPAKTMPLOTL-PLRBKUQPSA-N O=C(/C=C/C1=CC=CC=C1)OC1=CC(OC(=O)/C=C/C2=CC=CC=C2)=C2C(=O)C=C(C3=CC(OC(=O)/C=C/C4=CC=CC=C4)=C(OC(=O)/C=C/C4=CC=CC=C4)C=C3)OC2=C1.O=C(Cl)/C=C/C1=CC=CC=C1.O=C1C=C(C2=CC(O)=C(O)C=C2)OC2=CC(O)=CC(O)=C12 Chemical compound O=C(/C=C/C1=CC=CC=C1)OC1=CC(OC(=O)/C=C/C2=CC=CC=C2)=C2C(=O)C=C(C3=CC(OC(=O)/C=C/C4=CC=CC=C4)=C(OC(=O)/C=C/C4=CC=CC=C4)C=C3)OC2=C1.O=C(Cl)/C=C/C1=CC=CC=C1.O=C1C=C(C2=CC(O)=C(O)C=C2)OC2=CC(O)=CC(O)=C12 SWFOPAKTMPLOTL-PLRBKUQPSA-N 0.000 description 1
- NPMWKVHIVDQTCJ-PLRBKUQPSA-N O=C(/C=C/C1=CC=CC=C1)OCCOC1=CC(OC(=O)/C=C/C2=CC=CC=C2)=C2C(=O)C=C(C3=CC(OCCOC(=O)/C=C/C4=CC=CC=C4)=C(OCCOC(=O)/C=C/C4=CC=CC=C4)C=C3)CC2=C1.O=C(Cl)/C=C/C1=CC=CC=C1.O=C1C=C(C2=CC(OCCO)=C(OCCO)C=C2)OC2=CC(OCCO)=CC(O)=C12 Chemical compound O=C(/C=C/C1=CC=CC=C1)OCCOC1=CC(OC(=O)/C=C/C2=CC=CC=C2)=C2C(=O)C=C(C3=CC(OCCOC(=O)/C=C/C4=CC=CC=C4)=C(OCCOC(=O)/C=C/C4=CC=CC=C4)C=C3)CC2=C1.O=C(Cl)/C=C/C1=CC=CC=C1.O=C1C=C(C2=CC(OCCO)=C(OCCO)C=C2)OC2=CC(OCCO)=CC(O)=C12 NPMWKVHIVDQTCJ-PLRBKUQPSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241000210053 Potentilla elegans Species 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- KJQFBVYMGADDTQ-UHFFFAOYSA-N S-butyl-DL-homocysteine (S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CCC(N)C(O)=O KJQFBVYMGADDTQ-UHFFFAOYSA-N 0.000 description 1
- ARCJQKUWGAZPFX-KBPBESRZSA-N S-trans-stilbene oxide Chemical compound C1([C@H]2[C@@H](O2)C=2C=CC=CC=2)=CC=CC=C1 ARCJQKUWGAZPFX-KBPBESRZSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical group [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 206010041303 Solar dermatitis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 239000003490 Thiodipropionic acid Substances 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- SFRPDSKECHTFQA-ONOWFSFQSA-N [(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] propanoate Chemical compound CCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SFRPDSKECHTFQA-ONOWFSFQSA-N 0.000 description 1
- VHIACQPOQXQWQJ-BQYQJAHWSA-N [(e)-3-chloro-3-methoxyprop-1-enyl]benzene Chemical compound COC(Cl)\C=C\C1=CC=CC=C1 VHIACQPOQXQWQJ-BQYQJAHWSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 125000003525 allosyl group Chemical group 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 239000011795 alpha-carotene Substances 0.000 description 1
- 235000003903 alpha-carotene Nutrition 0.000 description 1
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 125000003420 altrosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 235000020396 apricot nectar Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 229960001799 aurothioglucose Drugs 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical class CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 description 1
- FQUNFJULCYSSOP-UHFFFAOYSA-N bisoctrizole Chemical compound N1=C2C=CC=CC2=NN1C1=CC(C(C)(C)CC(C)(C)C)=CC(CC=2C(=C(C=C(C=2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)O)=C1O FQUNFJULCYSSOP-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229910000420 cerium oxide Inorganic materials 0.000 description 1
- DRVWBEJJZZTIGJ-UHFFFAOYSA-N cerium(3+);oxygen(2-) Chemical class [O-2].[O-2].[O-2].[Ce+3].[Ce+3] DRVWBEJJZZTIGJ-UHFFFAOYSA-N 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- LAAPRQODJPXAHC-AATRIKPKSA-N coniferyl benzoate Chemical compound C1=C(O)C(OC)=CC(\C=C\COC(=O)C=2C=CC=CC=2)=C1 LAAPRQODJPXAHC-AATRIKPKSA-N 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000003581 cosmetic carrier Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- AIHCVGFMFDEUMO-UHFFFAOYSA-N diiodosilane Chemical compound I[SiH2]I AIHCVGFMFDEUMO-UHFFFAOYSA-N 0.000 description 1
- 235000019304 dilauryl thiodipropionate Nutrition 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- PWWSSIYVTQUJQQ-UHFFFAOYSA-N distearyl thiodipropionate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCCCCCCCC PWWSSIYVTQUJQQ-UHFFFAOYSA-N 0.000 description 1
- 235000019305 distearyl thiodipropionate Nutrition 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- HUVYTMDMDZRHBN-UHFFFAOYSA-N drometrizole trisiloxane Chemical compound C[Si](C)(C)O[Si](C)(O[Si](C)(C)C)CC(C)CC1=CC(C)=CC(N2N=C3C=CC=CC3=N2)=C1O HUVYTMDMDZRHBN-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000004872 foam stabilizing agent Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 235000015201 grapefruit juice Nutrition 0.000 description 1
- 125000001503 gulosyl group Chemical group C1([C@H](O)[C@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000003722 gum benzoin Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000004021 humic acid Substances 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 150000002432 hydroperoxides Chemical class 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 125000002951 idosyl group Chemical group C1([C@@H](O)[C@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N iron (II) ion Substances [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 229940033355 lauric acid Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 235000008486 nectar Nutrition 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940038580 oat bran Drugs 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- SOQBVABWOPYFQZ-UHFFFAOYSA-N oxygen(2-);titanium(4+) Chemical class [O-2].[O-2].[Ti+4] SOQBVABWOPYFQZ-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-O phenylazanium Chemical compound [NH3+]C1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-O 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 239000011252 protective cream Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012713 reactive precursor Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- WWDMJSSVVPXVSV-YCNIQYBTSA-N retinyl ester Chemical compound CC1CCCC(C)(C)C1\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O WWDMJSSVVPXVSV-YCNIQYBTSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229960002718 selenomethionine Drugs 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- ARCJQKUWGAZPFX-UHFFFAOYSA-N stilbene oxide Chemical compound O1C(C=2C=CC=CC=2)C1C1=CC=CC=C1 ARCJQKUWGAZPFX-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 150000001629 stilbenes Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-M succinate(1-) Chemical compound OC(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-M 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 125000004024 talosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 235000019303 thiodipropionic acid Nutrition 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 235000015113 tomato pastes and purées Nutrition 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
- RNWHGQJWIACOKP-UHFFFAOYSA-N zinc;oxygen(2-) Chemical class [O-2].[Zn+2] RNWHGQJWIACOKP-UHFFFAOYSA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Definitions
- the invention relates to compounds of the formula I
- UV filters have been developed which, applied to the skin in the form of creams, lotions or gels, can effectively delay the development of sunburn even when the incidence of solar rays is relatively high.
- the UV filter present in the pharmaceutical or cosmetic preparation forms a film or a layer on the surface of the skin and does not penetrate into deeper skin layers with other care substances present in the preparation.
- UV filters or sun protection agents thus act only by absorbing certain regions of sunlight, meaning that this radiation cannot penetrate into deeper layers of the skin.
- the most hazardous part of solar radiation is formed by the ultraviolet rays having a wavelength of less than 400 nm.
- the lower limit of the ultraviolet rays which reach the surface of the earth is limited by the absorption in the ozone layer to about 280 nm.
- the sun protection filters which are nowadays customary in cosmetics absorb in a wavelength range from 280 to 400 nm.
- This range includes UV-B rays having a wavelength between 280 and 320 nm, which play a decisive role in the formation of a solar erythema, and also UV-A rays, having a wavelength between 320 and 400 nm, which tan the skin but also age it, favour the triggering of an erythematous reaction or can exacerbate this reaction in certain people or even trigger phototoxic or photoallergic and irritative reactions.
- the object of care cosmetics is, wherever possible, to obtain the impression of a youthful skin.
- existing skin damage such as irregular pigmentation or the formation of wrinkles can be smoothed out by concealing powders or creams.
- Another approach is to protect the skin against environmental influences which lead to permanent damage and thus ageing of the skin. The idea is therefore to intervene in a preventative manner and thus to delay the ageing process.
- One example of this is the UV filters already mentioned which, by absorbing certain wavelength regions, prevent or at least reduce skin damage. While in the case of UV filters, the harmful phenomenon, the UV radiation, is screened from the skin, in another way, attempts have been made to support the natural defence or repair mechanisms of the skin against the harmful phenomenon.
- Another approach involves compensating for the defence functions of the skin toward harmful influences, which weaken with increasing age, by externally applying substances which are able to compensate for this diminishing defence or repair function.
- the skin has the ability to scavenge free radicals which are produced by external or internal stress factors. This ability decreases with increasing age, as a result of which the ageing process accelerates with increasing age.
- Substances which are to support or compensate for defence and repair functions in the skin must be able to be transported to their site of activity. In principle, there are two ways of achieving this. Either the substance is applied to the skin and penetrates through the external layers into the deeper layers of the skin, or the active ingredient is, for example, following oral administration, transported via the bloodstream to the site of activity.
- a further difficulty associated with the preparation of cosmetics is the fact that active ingredients which are to be incorporated into cosmetic formulations are often unstable and may become damaged in the formulation.
- the damage can be caused, for example, as a result of a reaction with atmospheric oxygen or as a result of the absorption of UV rays.
- the molecules damaged in this way can, as a result of a change in their structure, for example, change their colour and/or lose their effectiveness.
- DE 195 08 608 describes an unstable cosmetic composition for protection against UV rays of wavelength between 280 and 400 nm which comprises at least one tetraalkylquercetin in a cosmetically acceptable oil-based medium, and novel tetraalkylquercetins.
- FR 2 687 572 describes the use of flavonoids which do not have a double bond at position 2, 3 or do not simultaneously have a double bond at position 2, 3 and a hydroxyl group at position 3, for the preparation of cosmetic compositions, and as active ingredients for protecting the skin, the hair or cosmetic compositions against singlet oxygen.
- EP 0 716 847 A1 describes a cosmetic or dermatological active ingredient combination of cinnamic acid derivatives and flavone glycosides.
- the active ingredient combination here acts as an antioxidant. It is suitable for the combating or the prophylaxis of skin ageing.
- the active ingredient combination may also comprise UV filter substances as a further constituent.
- U.S. Pat. No. 5,665,367 describes a skincare composition which comprises retinol or a retinyl ester and a flavonoid chosen from the group consisting of naringenin and quercetin, which comprises a suitable cosmetic carrier.
- the composition can also comprise UV filters as a further component.
- FR 2 708 851 describes a cosmetic composition which comprises nanopigments and, as antioxidants, flavonoids.
- a further ingredient which may be present is also UV-A or UV-B filters.
- An object of the invention is to provide compounds which both act as antioxidants and also are able to effect protection against UV radiation.
- Y is O, S or NH
- a single or a double bond may be provided between carbon atoms C-2 and C-3,
- R 1 , R 2 , R 3 , R 4 and R 5 may be identical or different and, independently of one another are —H, —OH or —OA, and A is a group which absorbs UV radiation, preferably in the UV-A and/or UV-B region, which is chosen from the group formed from
- the compounds preferably have a structure of the formula II
- R 1 , R 2 , R 3 , R 4 and R 5 have the meanings given above and below.
- the flavonoids which form the base substance of the compounds of the formula I have activity as antioxidants and/or free-radical scavengers. Their combination with groups which exhibit a suitable absorption in the UV region provides a new class of compound which has very interesting properties.
- the flavonoids used as base substances themselves exhibit a certain protective action against UVA radiation. Therefore, by combining them with UV-absorbing groups, it is possible to provide UVA/B broad-band filters which also have an antioxidative effect.
- the groups are chosen such that they exhibit an absorption maximum in particular in the wavelength ranges of UVA and of UVB radiation which are particularly harmful for the skin.
- the UVB portion of sunlight covers the range from 280 to 320 nm, and the UVA radiation the range >320 nm, which directly borders the visible light region.
- UV broad-band filters of this type can be used, for example, in a large number of cosmetics.
- compounds of the formula I also have a stabilizing action on formulations which are used for cosmetics.
- the latter thus remain stable for longer and do not change their appearance.
- the effectiveness of the ingredients, e.g. vitamins is also retained. This is particularly advantageous in the case of sunscreen compositions since these cosmetics are subjected to particularly high stresses by UV rays.
- the substances of the formula I generally act as free-radical scavengers.
- Such free radicals are produced not only as a result of sunlight, but are formed under a variety of conditions.
- Examples are anoxia which block the electron flow upstream of the cytochrome oxidases and bring about the formation of superoxide radical anions; inflammations which are associated inter alia with the formation of superoxide anions as a result of membrane NADPH oxidase of leukocytes which, however, are also associated with the formation (as a result of disproportionation in the presence of iron(II) ions) of hydroxyl radicals and other reactive species normally involved in the phenomenon of phagocytosis; and lipid autoxidation which is generally initiated by a hydroxyl radical and produces lipidic alkoxy radicals and hydroperoxides.
- the compounds of the formula I also act as enzyme inhibitors. For example, they inhibit histidine decarboxylase, protein kinases, elastase, aldose reductase and hyaluronidase, which would make it possible to maintain the entirety of the base substance of vascular sheaths. In addition, they do not specifically inhibit catechol O-methyltransferase, as a result of which the amount of available catecholamines and, consequently, vascular strength can be increased. As a further effect, they inhibit AMP phosphodiesterase, as a result of which the substances may have potential for inhibiting platelet aggregation.
- Compounds of the formula I are in most cases not used without a diluent, but are incorporated into suitable formulations, such as creams, ointments or lotions.
- suitable formulations such as creams, ointments or lotions.
- the compounds can be used by application to the skin, but systemic transportation is also conceivable.
- the properties of the compounds of the formula I have to be matched to the conditions in question. Modification of the solubility in oil or water is possible by introducing corresponding groups into the molecule.
- Compounds which have been found to be suitable are those where in addition R 1 , R 2 , R 3 , R 4 and R 5 , independently of one another, have the meanings of —H, —OH, —OA, with A having the meaning given above, or one of the following meanings:
- the hydroxyl groups of the flavonoid base substance are etherified with suitable alcohols.
- a particularly suitable alkyl group is the 2-ethylhexyl group.
- the solubility in oil can also be improved by, for example, esterifying the hydroxyl groups of the flavonoid base substance with 2-ethylhexanecarboxylic acid.
- radicals are obtained by esterification with monocarboxylic acids, such as butyric acid, valeric acid, hexanoic acid, sorbic acid, ascorbic acid or lauric acid. These radicals promote the transportation of the compound through biological membranes. In the cell, the base substance can then be liberated by cleaving off the carboxylic acids using esterases.
- monocarboxylic acids such as butyric acid, valeric acid, hexanoic acid, sorbic acid, ascorbic acid or lauric acid.
- the solubility in water can be improved by introducing sulphate or phosphate groups into the molecule. Suitable for this are either compounds with one, two or three sulphate groups in the molecule, or mixtures of different sulphates or phosphates.
- hexosyl radicals for example allosyl, altrosyl, galactosyl, gulosyl, idosyl, mannosyl and talosyl, can also be used advantageously in some instances. It may also be advantageous to use pentosyl radicals.
- the glucosyl radicals can be bonded to the base substance by means of ⁇ - or ⁇ -glycoside bonds.
- a preferred disaccharide is, for example, 6-0-(6-deoxy- ⁇ -L-mannopyranosyl)- ⁇ -D-glucopyranoside.
- the radicals can be introduced, for example, starting from the known flavonoid base substances.
- alkyl chains can be introduced by reacting the base substance with the corresponding alkyl halides under the action of a strong base in a suitable solvent, for example dimethylformamide. If the radicals R 1 to R 5 bind as esters, this can be carried out, for example, by reaction with a corresponding acid chloride.
- Scheme I shows examples of a few precursors of radicals which are suitable for introduction of the radicals in the respective base substance.
- —X is a suitable leaving group, for example a halide. This list is only given by way of example and shows only a small fraction of the number of possible precursors.
- the compounds of the formula I can either be used as pure compounds, or it is also possible to use mixtures, this term here being understood as meaning both isomeric mixtures and also mixtures of compounds of the formula I which have different substitution patterns, i.e. carry, for example, a different number of substituents —OA.
- reaction of the flavonoid base substances with the corresponding reactive precursors of the radicals R 1 to R 5 is carried out by methods known to the person skilled in the art and in customary solvents.
- Suitable solvents are, for example, chlorinated hydrocarbons, dimethyl sulphoxide, dimethylformamide etc.
- the compounds of the formula I may display an advantageous effect on the skin.
- the invention thus also provides a cosmetic or pharmaceutical formulation comprising at least one compound of the formula I.
- the positive effect of the cosmetic or pharmaceutical preparation according to the invention is presumably based on the effect of the compounds of the formula I as antioxidants or free-radical scavengers in combination with an action as UV filters.
- the compounds of the formula I should be able to penetrate into deeper layers of the skin.
- the compounds of the formula I can have sufficient lipophilicity in order to be able to penetrate through the outer layer of the skin into epidermal layers.
- Another possibility involves also providing corresponding transportation agents, for example liposomes, which permit transportation of the compounds of the formula I through the external layers of skin, in the preparation.
- a systemic transportation of the compounds of the formula I is also conceivable.
- the preparation is then formulated, for example, such that it is suitable for oral administration.
- the one or more compounds of the formula I can be incorporated into cosmetic formulations in the customary manner.
- administration forms such as capsules, sugar-coated tablets, powders, tablet solutions or solutions are suitable.
- Examples which may be mentioned of administration forms of the cosmetic or pharmaceutical formulations according to the invention for external use are: solutions, suspensions, emulsions, PIT emulsions, pastes, ointments, gels, creams, lotions, powders, soaps, surfactant-containing cleansing preparations, oils, aerosols and sprays. Further application forms are, for example, sticks, shampoos and shower preparations. Customary carriers, auxiliaries and optionally further active ingredients may be added to the formulation.
- auxiliaries originate from the group of preservatives, antioxidants, stabilizers, solubility promoters, vitamins, colorants, odour improvers.
- Ointments, pastes, creams and gels may comprise the customary carriers, e.g. animal and vegetable fats, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silica, talc and zinc oxide or mixtures of these substances.
- customary carriers e.g. animal and vegetable fats, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silica, talc and zinc oxide or mixtures of these substances.
- Powders and sprays may comprise the customary carriers, e.g. lactose, talc, silica, aluminium hydroxide, calcium silicate and polyamide powder or mixtures of these substances.
- Sprays can additionally comprise customary propellants, e.g. chlorofluorocarbons, propane/butane or dimethyl ether.
- Solutions and emulsions can comprise the customary carriers, such as solvents, solubility promoters and emulsifiers, e.g. water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol, oils, in particular cottonseed oil, peanut oil, maize germ oil, olive oil, castor oil and sesame oil, glycerol fatty acid esters, polyethylene glycols and fatty acid esters of sorbitan or mixtures of these substances.
- solvents such as solvents, solubility promoters and emulsifiers, e.g. water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol, oils, in particular cottonseed oil,
- Soaps can comprise the customary carriers, such as alkali metal salts of fatty acids, salts of fatty acid monoesters, fatty acid protein hydrolysates, isethionates, lanolin, fatty alcohol, plant oils, plant extracts, glycerol, sugars or mixtures of these substances.
- customary carriers such as alkali metal salts of fatty acids, salts of fatty acid monoesters, fatty acid protein hydrolysates, isethionates, lanolin, fatty alcohol, plant oils, plant extracts, glycerol, sugars or mixtures of these substances.
- Surfactant-containing cleansing products can comprise the customary carrier substances, such as salts of fatty alcohol sulphates, fatty alcohol ether sulphates, sulphosuccinic monoesters, fatty acid protein hydrolysates, isethionates, imidazolinium derivatives, methyl taurates, sarcosinates, fatty acid amide ether sulphates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable and synthetic oils, lanolin derivatives, ethoxylated glycerol fatty acid esters or mixtures of these substances.
- customary carrier substances such as salts of fatty alcohol sulphates, fatty alcohol ether sulphates, sulphosuccinic monoesters, fatty acid protein hydrolysates, isethionates, imidazolinium derivatives, methyl taurates, sarcosinates, fatty acid amide ether sulph
- Face and body oils can comprise the customary carrier substances such as synthetic oils, such as fatty acid esters, fatty alcohols, silicone oils, natural oils, such as vegetable oils and oily plant extracts, paraffin oils, lanolin oils or mixtures of these substances.
- synthetic oils such as fatty acid esters, fatty alcohols, silicone oils, natural oils, such as vegetable oils and oily plant extracts, paraffin oils, lanolin oils or mixtures of these substances.
- Further typically cosmetic application forms are also lipsticks, lipcare sticks, mascara, eyeliner, eyeshadow, blusher, powder make-up, emulsion make-up and wax make-up, and sunscreen, presun and aftersun preparations.
- the cosmetic preparation according to the invention is particularly suitable for protecting human skin against ageing processes and against oxidative stress, i.e. against damage caused by free radicals, as are produced, for example, by solar irradiation, heat or other influences.
- they are in various administration forms customarily used for this application.
- it may in particular be in the form of a lotion or emulsion, such as in the form of a cream or milk (O/W, W/O, O/W/O, W/O/W), in the form of oily-alcoholic, oily-aqueous or aqueous-alcoholic gels or solutions, in the form of solid sticks or may be formulated as an aerosol.
- the formulation may comprise cosmetic auxiliaries which are customarily used in this type of preparation, such as, for example, thickeners, emollients, moisturizers, interface-active agents, emulsifiers, preservatives, antifoams, perfumes, waxes, lanolin, propellants, dyes and/or pigments which colour the composition itself or the skin, and other ingredients customarily used in cosmetics.
- cosmetic auxiliaries which are customarily used in this type of preparation, such as, for example, thickeners, emollients, moisturizers, interface-active agents, emulsifiers, preservatives, antifoams, perfumes, waxes, lanolin, propellants, dyes and/or pigments which colour the composition itself or the skin, and other ingredients customarily used in cosmetics.
- dispersant or solubilizer it is possible to use an oil, wax or other fatty substance, a lower monoalcohol or a lower polyol or mixtures thereof.
- Particularly preferred monoalcohols or polyols include ethanol, isopropanol, propylene glycol, glycerol and sorbitol.
- a preferred embodiment of the invention is an emulsion in the form of a protective cream or milk and which, apart from the compound(s) of the formula I, comprises, for example, fatty alcohols, fatty acids, fatty acid esters, in particular triglycerides of fatty acids, lanolin, natural and synthetic oils or waxes and emulsifiers in the presence of water.
- Further preferred embodiments are oily lotions based on natural or synthetic oils and waxes, lanolin, fatty acid esters, in particular triglycerides of fatty acids, or oily-alcoholic lotions based on a lower alcohol, such as ethanol, or a glycerol, such as propylene glycol, and/or a polyol, such as glycerol, and oils, waxes and fatty acid esters, such as triglycerides of fatty acids.
- a lower alcohol such as ethanol
- a glycerol such as propylene glycol
- a polyol such as glycerol
- the cosmetic preparation according to the invention can also be in the form of an alcoholic gel which comprises one or more lower alcohols or polyols, such as ethanol, propylene glycol or glycerol, and a thickener, such as siliceous earth.
- the oily-alcoholic gels also comprise natural or synthetic oil or wax.
- the solid sticks consist of natural or synthetic waxes and oils, fatty alcohols, fatty acids, fatty acid esters, lanolin and other fatty substances. If a preparation is formulated as an aerosol, the customary propellants, such as alkanes, fluoroalkanes and chlorofluoroalkanes are usually used.
- the cosmetic formulation can also be used to protect the hair against photochemical damage in order to prevent changes of colour shades, decoloration or damage of a mechanical nature.
- a suitable formulation is in the form of a shampoo, lotion, gel or emulsion for rinsing out, the formulation in question being applied before or after shampooing, before or after colouring or bleaching or before or after permanent waving. It is also possible to choose a formulation in the form of a lotion or gel for styling or treating the hair, in the form of a lotion or gel for brushing or blow-waving, in the form of a hair lacquer, permanent waving composition, colorant or bleach for the hair.
- the cosmetic or pharmaceutical formulation may comprise various adjuvants used in this type of composition, such as interface-active agents, thickeners, polymers, emollients, preservatives, foam stabilizers, electrolytes, organic solvents, silicone derivatives, oils, waxes, antigrease agents, dyes and/or pigments which colour the composition itself or the hair, or other ingredients customarily used for hair care.
- adjuvants used in this type of composition such as interface-active agents, thickeners, polymers, emollients, preservatives, foam stabilizers, electrolytes, organic solvents, silicone derivatives, oils, waxes, antigrease agents, dyes and/or pigments which colour the composition itself or the hair, or other ingredients customarily used for hair care.
- compositions according to the invention can be prepared using techniques which are well known to the person skilled in the art.
- a cosmetic preparation comprising one or more compounds of formula I is applied to the skin or the hair.
- Sensitized hair is understood here as meaning hair which has been subjected to a chemical treatment, such as a permanent waving treatment, a colouring process or bleaching process.
- the protective action against UV radiation can be improved if the formulation comprises one or more UV filters.
- UV filters are suitable for a combination. Particular preference is given to those UV filters whose physiological safety has already been demonstrated. There are many tried and tested substances known from the specialist literature both for UVA and also UVB filters, e.g.
- N,N,N,-trimethyl-4-(2-oxoborn-3-ylidenemethyl)anilinium methylsulphate e.g. Mexoryl® SK
- Mexoryl® SK 2-oxoborn-3-ylidenemethyl
- benzophenones such as
- methoxycinnamic esters such as
- octyl methoxycinnamate e.g. Eusolex® 2292
- isopentyl 4-methoxycinnamate e.g. as a mixture of the isomers (e.g. Neo Heliopan® E 1000),
- salicylate derivatives such as
- 2-ethylhexyl salicylate e.g. Eusolex® OS
- organic UV filters are usually incorporated into cosmetic formulations in an amount of from 0.5 to 10% by weight, preferably 1-8%.
- organic UV filters are usually incorporated into cosmetic formulations in an amount of from 0.5 to 20% to 20% by weight, preferably 1-15%.
- Conceivable inorganic UV filters are those from the group of titanium dioxides, such as, for example, coated titanium dioxide (e.g. Eusolex® T-2000, Eusolex® T-AQUA), zinc oxides (e.g. Sachtotec®), iron oxides and also cerium oxides. These inorganic UV filters are usually incorporated into cosmetic formulations in an amount of from 0.5 to 20% by weight, preferably 2-10%.
- the organic or inorganic UV filters can be combined as desired with the compounds of the formula I. Based on the weight, the ratio of UV filters to the compounds of the formula I is preferably chosen between 1:10 and 10:1, in particular between 1:5 and 5:1.
- the protecting action against oxidative stress or against the effect of free radicals can be further improved if the formulation comprises one or more further antioxidants.
- amino acids e.g. glycine, histidine, tyrosine, tryptophan
- imidazoles e.g. urocanic acid
- peptides such as D,L-carnosine, D-carnosine, L-carnosine and derivatives thereof (e.g. anserine)
- carotenoids e.g. ⁇ -carotene, ⁇ -carotene, lycopene
- carotenes e.g. ⁇ -carotene, ⁇ -carotene, lycopene
- chlorogenic acid and derivatives thereof e.g.
- thiols e.g. thioredoxin, glutathione, cysteine, cystine, cystamine and the glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholesteryl and glyceryl esters thereof), and salts thereof, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and derivatives thereof (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts), and sulphoximine compounds (e.g.
- buthionine-sulphoximine in very low tolerated doses (e.g. pmol to pmol/kg), and also (metal) chelating agents, (e.g. ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), ⁇ -hydroxy acids (e.g.
- vitamin A palmitate coniferyl benzoate of benzoin resin, rutinic acid and derivatives thereof, ⁇ -glycosyl rutin, ferulic acid, furfurylideneglucitol, carnosine, butylhydroxytoluene, butylhydroxyanisole, nordihydroguaiaretic acid, trihydroxy-butyrophenone, quercetin, uric acid and derivatives thereof, mannose and derivatives thereof, zinc and derivatives thereof (e.g. ZnO, ZnSO 4 ), selenium and derivatives thereof (e.g. selenomethionine), stilbenes and derivatives thereof (e.g. stilbene oxide, trans-stilbene oxide).
- benzoin resin rutinic acid and derivatives thereof, ⁇ -glycosyl rutin, ferulic acid, furfurylideneglucitol, carnosine, butylhydroxytoluene, butylhydroxyanisole, nordihydroguaiaretic
- Oxynex® L LIQUID DL- ⁇ -tocopherol
- citric acid and lecithin e.g. Oxynex® LM
- BHT butylhydroxytoluene
- L-(+)-ascorbyl palmitate e.g. Oxynex® 2004.
- the antioxidants can be combined as desired with the compounds of the formula I. Based on the weight, the ratio of the antioxidant to the compounds of the formula I is preferably chosen between 1:10 and 10:1, in particular between 1:5 and 5:1.
- the formulation according to the invention may also comprise, as ingredient, ectoin (2-methyl-1,4,5,6-tetrahydropyrimidine-4-carboxylic acid) and in that case effects protection of the Langerhans cells.
- ectoin (2-methyl-1,4,5,6-tetrahydropyrimidine-4-carboxylic acid)
- the formulation according to the invention develops an antiinflammatory action.
- the cosmetic or pharmaceutical formulation comprising at least one compound of the formula I is suitable particularly for protecting the body's cells against oxidative stress, in particular for reducing skin ageing.
- the foodstuffs which can be enriched according to the present invention with one or more compounds of the formula I include all materials which are suitable for consumption by animals or for consumption by humans, for example vitamins and provitamins thereof, fats, minerals or amino acids.
- the foodstuffs may be solid, or else liquid, i.e. be in the form of a drink).
- Foodstuffs which can be enriched according to the present invention with one or more compounds of the formula I are, for example, also foodstuffs which originate from a single natural source, such as, for example, sugars, unsweetened juice, nectar or puree from a single plant species, such as, for example, unsweetened apple juice (e.g.
- foodstuffs which can be enriched according to the present invention with one or more compounds of the formula I are corn or cereals of a single plant species and materials which are prepared from such plant species, such as, for example, cereal syrup, rye flour, wheatmeal or oat bran. Mixtures of such foodstuffs are also suitable for being enriched according to the present invention with one or more compounds of the formula I, for example multivitamin preparations, mineral substance mixtures or sugared juice.
- the foodstuffs which can be enriched according to the present invention with one or more compounds of the formula I thus include all palatable combinations of carbohydrates, lipids, proteins, inorganic elements, trace elements, vitamins, water or active metabolytes of plants and animals.
- the foodstuffs which can be enriched according to the present invention with one or more compounds of the formula I are preferably used orally, e.g. in the form of foods, pills, tablets, capsules, powders, syrup, solutions or suspensions.
- compounds of the formula I are also suitable as medicaments.
- they have a supporting or substituting action for natural mechanisms which scavenge free radicals within the body.
- the compounds of the formula I may sometimes be compared with free-radical scavengers such as vitamin C.
- Compounds of the formula I can be used, for example, for the preventative treatment of inflammation and allergies of the skin, and in certain cases for preventing certain types of cancer.
- compounds of the formula I are suitable in particular for the preparation of a medicament for the treatment of inflammations, allergies and irritations, in particular of the skin.
- medicaments which act as vein tonics, as agents for increasing the strength of blood capillaries, as inhibitants for cuperose, as inhibitors of chemical, physical or actinic erythemas, as agents for treating sensitive skin, as decongestants, as dehydrating agents, as weight-loss agents, as antiwrinkle agents, as stimulators of the synthesis of components of the extracellular matrix, as strengthening agents for improving elasticity of the skin and as anti-ageing agents.
- a further subject-matter of the invention relates to the stabilization of UV filters.
- a known and high-performance class of light protection filter substances is formed by the dibenzoylmethane derivatives.
- a disadvantage is that these substances are very readily decomposed by UV light and thus lose their protective properties.
- One example which may be mentioned of a commercially available light protection filter from this class of compound is 4-(tert-butyl)-4′-methoxydibenzoylmethane, which has the structure shown below.
- 3′,4′,7-tribenzyl-2-(1-(4-tert-butylphenyl)-3-(4-oxophenyl)propane-1,3-dione)quercetin is dissolved in 200 ml of methanol and hydrogenated using 0.3 g of 10% Pd/carbon at 1 bar. Removal of the catalyst and of the solvent used gives the desired product.
- compositions of cosmetic formulations are given below.
- Care lotion (W/O) for application to the skin % by wt A Compound 7 1.00 Polyglyceryl-2 dipolyhydroxystearate 5.00 Beeswax 0.50 Zinc stearate 0.50 Hexyl laurate 9.00 Cetyl isononanoate 6.00 Shea butter 0.50 DL- ⁇ -Tocopherol acetate 1.00 B Glycerol 5.00 Magnesium sulphate heptahydrate 1.00 Preservative q.s. Water, demineralized ad 100.00
- Phase A is heated to 75° C. and phase B is heated to 80° C. With stirring, phase B is slowly added to phase A. Following homogenization, the mixture is cooled with stirring. At a temperature of 40° C., perfume substances are added.
- the preservatives used are:
- Magnesium sulphate heptahydrate 1.00 Preservative q.s. Water, demineralized ad 100.00
- Phase A is heated to 75° C. and phase B is heated to 80° C. With stirring, phase B is slowly added to phase A. Following homogenization, the mixture is cooled with stirring. At a temperature of 40° C., perfume substances are added.
- Phase A and phase B are heated separately to 75° C.
- Phase C is then slowly added to phase B and stirred until homogenized.
- the resulting B/C mixture is added to phase A at a temperature of 75° C., and the mixture is homogenized.
- Perfume substances are added after cooling to 35° C.
- a Compound 7 1.00 Paraffin 2.00 Isohexadecane 2.00 Isopropyl palmitate 3.00 Soya oil 0.50 Dimethicone 1.00 Cetyl alcohol 1.00 Sorbitol stearate 1.50 Cetyl alcohol (and) cetyl glucoside 4.00 ( ⁇ )- ⁇ -Bisabolol 0.30 B Water, demineralized ad 100.00 Glycerol 87% 10.00 D-Panthenol 0.50 (D+)-Biotin 0.05 Preservative q.s. C Xanthan gum 0.30 D Perfume 0.20
- Phase A and phase B are heated separately to 75° C. Phase C is then slowly added to phase B and stirred until homogenized. The resulting B/C mixture is added to phase A at a temperature of 75° C. and the mixture is homogenized. After cooling to 35° C., perfume substances are added.
- Phase B is slowly added with stirring to phase A. Following homogenization, the mixture is cooled with stirring.
- phase A The constituents of phase A, with the exception of Pemulen® TR-2, are combined and heated to 80° C. The Pemulen® TR-2 is then added with stirring.
- Phase B is slowly added to phase A with stirring. Following homogenization, the mixture is cooled with stirring.
- Carbomer Ultrez-10 is completely dispersed in the water of phase B. Phase C is then slowly added and homogenized.
- phase A the water is firstly added to the sodium hydroxide solution and then the Eusolex® 232 is added and completely dissolved with stirring. After a clear solution has been obtained, the further constituents of phase A are added. Phase A is then added in portions to the mixture of phases B and C, the mixture being homogenized after each addition.
- the preservative used is:
- the Pemulen® TR-1 is dissolved in the water of phase D.
- the tris(hydroxymethyl)aminomethane is dissolved in the water of phase C and the solution is added to phase D.
- the tris(hydroxymethyl)aminomethane is dissolved in the water of phase B and then the Eusolex® 232 is added with stirring.
- the further constituents of phase B are added and then phase B is added to the mixture of phases C and D and homogenized.
- the constituents of phase A are combined and heated. Phase A is then added to the mixture of the other phases with homogenization.
- the Pemulen® TR-1 is dissolved in the water of phase D.
- the tris(hydroxymethyl)aminomethane is dissolved in the water of phase C and the solution is added to phase D.
- the tris(hydroxymethyl)aminomethane is dissolved in the water of phase B and then the Eusolex® 232 is added with stirring.
- the further constituents of phase B are added and then phase B is added to the mixture of phases C and D and homogenized.
- the constituents of phase A are combined and heated. Phase A is then added to the mixture of the other phases with homogenization.
- phase A is heated to 75° C. and phase B is heated separately to 80° C.
- Phase B is added to phase A with homogenization. The mixture is then cooled with stirring.
- phase A is heated to 75° C. and phase B is heated separately to 80° C.
- Phase B is added to phase A with homogenization. The mixture is then cooled with stirring.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Cosmetics (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
Description
-
- where X, Y, R 1, R2 R3, R4 and R5 have the meanings defined herein.
- A suntan of the skin to whatever degree is regarded in today's society as attractive and as an expression of vigour and sportiness. As well as this desired effect of the sun on the skin, a number of undesired secondary effects arise, such as sunburn or premature skin ageing and the formation of wrinkles. In the meantime, a number of performance UV filters have been developed which, applied to the skin in the form of creams, lotions or gels, can effectively delay the development of sunburn even when the incidence of solar rays is relatively high. The UV filter present in the pharmaceutical or cosmetic preparation forms a film or a layer on the surface of the skin and does not penetrate into deeper skin layers with other care substances present in the preparation. Known UV filters or sun protection agents thus act only by absorbing certain regions of sunlight, meaning that this radiation cannot penetrate into deeper layers of the skin. As is known, the most hazardous part of solar radiation is formed by the ultraviolet rays having a wavelength of less than 400 nm. The lower limit of the ultraviolet rays which reach the surface of the earth is limited by the absorption in the ozone layer to about 280 nm. The sun protection filters which are nowadays customary in cosmetics absorb in a wavelength range from 280 to 400 nm. This range includes UV-B rays having a wavelength between 280 and 320 nm, which play a decisive role in the formation of a solar erythema, and also UV-A rays, having a wavelength between 320 and 400 nm, which tan the skin but also age it, favour the triggering of an erythematous reaction or can exacerbate this reaction in certain people or even trigger phototoxic or photoallergic and irritative reactions.
- Skin damage is caused not only by sunlight, but also by other external influences, such as cold or warmth. In addition the skin is subject to natural ageing, as a result of which wrinkles appear and the elasticity of the skin decreases.
- The object of care cosmetics is, wherever possible, to obtain the impression of a youthful skin. In principle, there are various ways of achieving this object. For example, existing skin damage, such as irregular pigmentation or the formation of wrinkles can be smoothed out by concealing powders or creams. Another approach is to protect the skin against environmental influences which lead to permanent damage and thus ageing of the skin. The idea is therefore to intervene in a preventative manner and thus to delay the ageing process. One example of this is the UV filters already mentioned which, by absorbing certain wavelength regions, prevent or at least reduce skin damage. While in the case of UV filters, the harmful phenomenon, the UV radiation, is screened from the skin, in another way, attempts have been made to support the natural defence or repair mechanisms of the skin against the harmful phenomenon. Finally, another approach involves compensating for the defence functions of the skin toward harmful influences, which weaken with increasing age, by externally applying substances which are able to compensate for this diminishing defence or repair function. For example, the skin has the ability to scavenge free radicals which are produced by external or internal stress factors. This ability decreases with increasing age, as a result of which the ageing process accelerates with increasing age.
- Substances which are to support or compensate for defence and repair functions in the skin must be able to be transported to their site of activity. In principle, there are two ways of achieving this. Either the substance is applied to the skin and penetrates through the external layers into the deeper layers of the skin, or the active ingredient is, for example, following oral administration, transported via the bloodstream to the site of activity.
- A further difficulty associated with the preparation of cosmetics is the fact that active ingredients which are to be incorporated into cosmetic formulations are often unstable and may become damaged in the formulation. The damage can be caused, for example, as a result of a reaction with atmospheric oxygen or as a result of the absorption of UV rays. The molecules damaged in this way can, as a result of a change in their structure, for example, change their colour and/or lose their effectiveness.
- DE 195 08 608 describes an unstable cosmetic composition for protection against UV rays of wavelength between 280 and 400 nm which comprises at least one tetraalkylquercetin in a cosmetically acceptable oil-based medium, and novel tetraalkylquercetins.
- FR 2 687 572 describes the use of flavonoids which do not have a double bond at position 2, 3 or do not simultaneously have a double bond at position 2, 3 and a hydroxyl group at position 3, for the preparation of cosmetic compositions, and as active ingredients for protecting the skin, the hair or cosmetic compositions against singlet oxygen.
- EP 0 716 847 A1 describes a cosmetic or dermatological active ingredient combination of cinnamic acid derivatives and flavone glycosides. The active ingredient combination here acts as an antioxidant. It is suitable for the combating or the prophylaxis of skin ageing. The active ingredient combination may also comprise UV filter substances as a further constituent.
- U.S. Pat. No. 5,665,367 describes a skincare composition which comprises retinol or a retinyl ester and a flavonoid chosen from the group consisting of naringenin and quercetin, which comprises a suitable cosmetic carrier. The composition can also comprise UV filters as a further component.
- FR 2 708 851 describes a cosmetic composition which comprises nanopigments and, as antioxidants, flavonoids. A further ingredient which may be present is also UV-A or UV-B filters.
- An object of the invention is to provide compounds which both act as antioxidants and also are able to effect protection against UV radiation.
- Upon further study of the specification and appended claims, further objects and advantages of this invention will become apparent to those skilled in the art.
-
- where X is O, S or NH;
- Y is O, S or NH
- a single or a double bond may be provided between carbon atoms C-2 and C-3,
-
- and at least one of the groups R 1, R2, R3, R4 or R5 is formed by —OA.
-
- where R 1, R2, R3, R4 and R5 have the meanings given above and below.
- The flavonoids which form the base substance of the compounds of the formula I have activity as antioxidants and/or free-radical scavengers. Their combination with groups which exhibit a suitable absorption in the UV region provides a new class of compound which has very interesting properties.
- As well as their action as antioxidant, the flavonoids used as base substances themselves exhibit a certain protective action against UVA radiation. Therefore, by combining them with UV-absorbing groups, it is possible to provide UVA/B broad-band filters which also have an antioxidative effect. In this connection, the groups are chosen such that they exhibit an absorption maximum in particular in the wavelength ranges of UVA and of UVB radiation which are particularly harmful for the skin. The UVB portion of sunlight covers the range from 280 to 320 nm, and the UVA radiation the range >320 nm, which directly borders the visible light region. UV broad-band filters of this type can be used, for example, in a large number of cosmetics.
- As a result of their antioxidative effect, compounds of the formula I also have a stabilizing action on formulations which are used for cosmetics. By adding compounds of the formula I to the corresponding products, the latter thus remain stable for longer and do not change their appearance. In particular, in cases of longer-lasting application or prolonged storage, the effectiveness of the ingredients, e.g. vitamins, is also retained. This is particularly advantageous in the case of sunscreen compositions since these cosmetics are subjected to particularly high stresses by UV rays.
- The substances of the formula I generally act as free-radical scavengers. Such free radicals are produced not only as a result of sunlight, but are formed under a variety of conditions. Examples are anoxia which block the electron flow upstream of the cytochrome oxidases and bring about the formation of superoxide radical anions; inflammations which are associated inter alia with the formation of superoxide anions as a result of membrane NADPH oxidase of leukocytes which, however, are also associated with the formation (as a result of disproportionation in the presence of iron(II) ions) of hydroxyl radicals and other reactive species normally involved in the phenomenon of phagocytosis; and lipid autoxidation which is generally initiated by a hydroxyl radical and produces lipidic alkoxy radicals and hydroperoxides.
- The compounds of the formula I also act as enzyme inhibitors. For example, they inhibit histidine decarboxylase, protein kinases, elastase, aldose reductase and hyaluronidase, which would make it possible to maintain the entirety of the base substance of vascular sheaths. In addition, they do not specifically inhibit catechol O-methyltransferase, as a result of which the amount of available catecholamines and, consequently, vascular strength can be increased. As a further effect, they inhibit AMP phosphodiesterase, as a result of which the substances may have potential for inhibiting platelet aggregation.
- These properties permit, for example, a use of compounds of the formula I for a large number of therapeutic applications. They are, for example, suitable for protecting DNA. Further uses arise from their effect as an antiviral agent, in particular as an agent against herpes. In addition, they can be used as bacteriostatic or bactericidal agents or else as antiinflammatory agents.
- Compounds of the formula I are in most cases not used without a diluent, but are incorporated into suitable formulations, such as creams, ointments or lotions. The compounds can be used by application to the skin, but systemic transportation is also conceivable. For this purpose, the properties of the compounds of the formula I have to be matched to the conditions in question. Modification of the solubility in oil or water is possible by introducing corresponding groups into the molecule. Compounds which have been found to be suitable are those where in addition R 1, R2, R3, R4 and R5, independently of one another, have the meanings of —H, —OH, —OA, with A having the meaning given above, or one of the following meanings:
- straight-chain or branched oxalkyl or carboxyalkyl group having 1 to 12 carbon atoms,
- straight-chain or branched oxalkenyl or carboxyalkenyl group having 2 to 12 carbon atoms,
- straight-chain or branched hydroxyoxalkyl group having 1 to 12 carbon atoms, where the hydroxyl group may be bonded to a primary or secondary carbon atom and, furthermore, the alkyl chain may also be interrupted by oxygen,
- sulphate group,
- phosphate group
- and a mono- or oligoglycosyl radical,
- where these groups may be substituted by alkyl, hydroxyl, alkoxy, amino, mono- and dialkylamino, sulphonic acid, carboxyl and/or halogen groups,
- and wherein at least one of the groups is an —OA group.
- To improve the solubility in oil, the hydroxyl groups of the flavonoid base substance are etherified with suitable alcohols. A particularly suitable alkyl group is the 2-ethylhexyl group.
- The solubility in oil can also be improved by, for example, esterifying the hydroxyl groups of the flavonoid base substance with 2-ethylhexanecarboxylic acid.
- Further suitable radicals are obtained by esterification with monocarboxylic acids, such as butyric acid, valeric acid, hexanoic acid, sorbic acid, ascorbic acid or lauric acid. These radicals promote the transportation of the compound through biological membranes. In the cell, the base substance can then be liberated by cleaving off the carboxylic acids using esterases.
- The solubility in water can be improved by introducing sulphate or phosphate groups into the molecule. Suitable for this are either compounds with one, two or three sulphate groups in the molecule, or mixtures of different sulphates or phosphates.
- Preference is also given to choosing those structures in which at least one of the radicals R 1, R2, R3, R4. and R5 is formed by a mono- or oligosaccharide. Preference is given here to hexosyl radicals, in particular rhamnosyl radicals and glucosyl radicals. However, other hexosyl radicals, for example allosyl, altrosyl, galactosyl, gulosyl, idosyl, mannosyl and talosyl, can also be used advantageously in some instances. It may also be advantageous to use pentosyl radicals. The glucosyl radicals can be bonded to the base substance by means of α- or β-glycoside bonds. A preferred disaccharide is, for example, 6-0-(6-deoxy-α-L-mannopyranosyl)-β-D-glucopyranoside.
- The compounds of the formula I are prepared by methods known per se to the person skilled in the art and are described in standard works such as Houben-Weyl, “Methoden der organischen Chemie” [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart.
- The radicals can be introduced, for example, starting from the known flavonoid base substances. Thus, alkyl chains can be introduced by reacting the base substance with the corresponding alkyl halides under the action of a strong base in a suitable solvent, for example dimethylformamide. If the radicals R 1 to R5 bind as esters, this can be carried out, for example, by reaction with a corresponding acid chloride. Scheme I shows examples of a few precursors of radicals which are suitable for introduction of the radicals in the respective base substance. Here, —X is a suitable leaving group, for example a halide. This list is only given by way of example and shows only a small fraction of the number of possible precursors. It is directly possible for the person skilled in the art to assign other suitable leaving groups, for example a tosylate group or a triflate group, instead of the halides. For example, introduction of the radicals bonded via an ester function is also possible via corresponding transesterification reactions.
- The compounds of the formula I can either be used as pure compounds, or it is also possible to use mixtures, this term here being understood as meaning both isomeric mixtures and also mixtures of compounds of the formula I which have different substitution patterns, i.e. carry, for example, a different number of substituents —OA.
- The reaction of the flavonoid base substances with the corresponding reactive precursors of the radicals R 1 to R5 is carried out by methods known to the person skilled in the art and in customary solvents. Suitable solvents are, for example, chlorinated hydrocarbons, dimethyl sulphoxide, dimethylformamide etc.
- The compounds of the formula I may display an advantageous effect on the skin. The invention thus also provides a cosmetic or pharmaceutical formulation comprising at least one compound of the formula I.
- The positive effect of the cosmetic or pharmaceutical preparation according to the invention is presumably based on the effect of the compounds of the formula I as antioxidants or free-radical scavengers in combination with an action as UV filters. In order to be able to develop their positive effect on the skin, the compounds of the formula I should be able to penetrate into deeper layers of the skin. For this, a number of possibilities are available. Firstly, the compounds of the formula I can have sufficient lipophilicity in order to be able to penetrate through the outer layer of the skin into epidermal layers. Another possibility involves also providing corresponding transportation agents, for example liposomes, which permit transportation of the compounds of the formula I through the external layers of skin, in the preparation. Finally, a systemic transportation of the compounds of the formula I is also conceivable. The preparation is then formulated, for example, such that it is suitable for oral administration.
- The one or more compounds of the formula I can be incorporated into cosmetic formulations in the customary manner. For internal use, administration forms such as capsules, sugar-coated tablets, powders, tablet solutions or solutions are suitable.
- Examples which may be mentioned of administration forms of the cosmetic or pharmaceutical formulations according to the invention for external use are: solutions, suspensions, emulsions, PIT emulsions, pastes, ointments, gels, creams, lotions, powders, soaps, surfactant-containing cleansing preparations, oils, aerosols and sprays. Further application forms are, for example, sticks, shampoos and shower preparations. Customary carriers, auxiliaries and optionally further active ingredients may be added to the formulation.
- Preferred auxiliaries originate from the group of preservatives, antioxidants, stabilizers, solubility promoters, vitamins, colorants, odour improvers.
- Ointments, pastes, creams and gels may comprise the customary carriers, e.g. animal and vegetable fats, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silica, talc and zinc oxide or mixtures of these substances.
- Powders and sprays may comprise the customary carriers, e.g. lactose, talc, silica, aluminium hydroxide, calcium silicate and polyamide powder or mixtures of these substances. Sprays can additionally comprise customary propellants, e.g. chlorofluorocarbons, propane/butane or dimethyl ether.
- Solutions and emulsions can comprise the customary carriers, such as solvents, solubility promoters and emulsifiers, e.g. water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol, oils, in particular cottonseed oil, peanut oil, maize germ oil, olive oil, castor oil and sesame oil, glycerol fatty acid esters, polyethylene glycols and fatty acid esters of sorbitan or mixtures of these substances.
- Suspensions can comprise the customary carriers such as liquid diluents, e.g. water, ethanol or propylene glycol, suspending agents, e.g. ethoxylated isostearyl alcohols, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar agar and tragacanth or mixtures of these substances.
- Soaps can comprise the customary carriers, such as alkali metal salts of fatty acids, salts of fatty acid monoesters, fatty acid protein hydrolysates, isethionates, lanolin, fatty alcohol, plant oils, plant extracts, glycerol, sugars or mixtures of these substances.
- Surfactant-containing cleansing products can comprise the customary carrier substances, such as salts of fatty alcohol sulphates, fatty alcohol ether sulphates, sulphosuccinic monoesters, fatty acid protein hydrolysates, isethionates, imidazolinium derivatives, methyl taurates, sarcosinates, fatty acid amide ether sulphates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable and synthetic oils, lanolin derivatives, ethoxylated glycerol fatty acid esters or mixtures of these substances.
- Face and body oils can comprise the customary carrier substances such as synthetic oils, such as fatty acid esters, fatty alcohols, silicone oils, natural oils, such as vegetable oils and oily plant extracts, paraffin oils, lanolin oils or mixtures of these substances.
- Further typically cosmetic application forms are also lipsticks, lipcare sticks, mascara, eyeliner, eyeshadow, blusher, powder make-up, emulsion make-up and wax make-up, and sunscreen, presun and aftersun preparations.
- All compounds or components which can be used in the cosmetic formulations are either known and available commercially or can be synthesized by known processes.
- The cosmetic preparation according to the invention is particularly suitable for protecting human skin against ageing processes and against oxidative stress, i.e. against damage caused by free radicals, as are produced, for example, by solar irradiation, heat or other influences. In this connection, they are in various administration forms customarily used for this application. For example, it may in particular be in the form of a lotion or emulsion, such as in the form of a cream or milk (O/W, W/O, O/W/O, W/O/W), in the form of oily-alcoholic, oily-aqueous or aqueous-alcoholic gels or solutions, in the form of solid sticks or may be formulated as an aerosol.
- The formulation may comprise cosmetic auxiliaries which are customarily used in this type of preparation, such as, for example, thickeners, emollients, moisturizers, interface-active agents, emulsifiers, preservatives, antifoams, perfumes, waxes, lanolin, propellants, dyes and/or pigments which colour the composition itself or the skin, and other ingredients customarily used in cosmetics.
- As dispersant or solubilizer it is possible to use an oil, wax or other fatty substance, a lower monoalcohol or a lower polyol or mixtures thereof. Particularly preferred monoalcohols or polyols include ethanol, isopropanol, propylene glycol, glycerol and sorbitol.
- A preferred embodiment of the invention is an emulsion in the form of a protective cream or milk and which, apart from the compound(s) of the formula I, comprises, for example, fatty alcohols, fatty acids, fatty acid esters, in particular triglycerides of fatty acids, lanolin, natural and synthetic oils or waxes and emulsifiers in the presence of water.
- Further preferred embodiments are oily lotions based on natural or synthetic oils and waxes, lanolin, fatty acid esters, in particular triglycerides of fatty acids, or oily-alcoholic lotions based on a lower alcohol, such as ethanol, or a glycerol, such as propylene glycol, and/or a polyol, such as glycerol, and oils, waxes and fatty acid esters, such as triglycerides of fatty acids.
- The cosmetic preparation according to the invention can also be in the form of an alcoholic gel which comprises one or more lower alcohols or polyols, such as ethanol, propylene glycol or glycerol, and a thickener, such as siliceous earth. The oily-alcoholic gels also comprise natural or synthetic oil or wax.
- The solid sticks consist of natural or synthetic waxes and oils, fatty alcohols, fatty acids, fatty acid esters, lanolin and other fatty substances. If a preparation is formulated as an aerosol, the customary propellants, such as alkanes, fluoroalkanes and chlorofluoroalkanes are usually used.
- The cosmetic formulation can also be used to protect the hair against photochemical damage in order to prevent changes of colour shades, decoloration or damage of a mechanical nature. In this case, a suitable formulation is in the form of a shampoo, lotion, gel or emulsion for rinsing out, the formulation in question being applied before or after shampooing, before or after colouring or bleaching or before or after permanent waving. It is also possible to choose a formulation in the form of a lotion or gel for styling or treating the hair, in the form of a lotion or gel for brushing or blow-waving, in the form of a hair lacquer, permanent waving composition, colorant or bleach for the hair. Apart from the compound(s) of the formula I, the cosmetic or pharmaceutical formulation may comprise various adjuvants used in this type of composition, such as interface-active agents, thickeners, polymers, emollients, preservatives, foam stabilizers, electrolytes, organic solvents, silicone derivatives, oils, waxes, antigrease agents, dyes and/or pigments which colour the composition itself or the hair, or other ingredients customarily used for hair care.
- The cosmetic preparations according to the invention can be prepared using techniques which are well known to the person skilled in the art.
- To protect the skin and/or natural or sensitized hair against solar rays, a cosmetic preparation comprising one or more compounds of formula I is applied to the skin or the hair. Sensitized hair is understood here as meaning hair which has been subjected to a chemical treatment, such as a permanent waving treatment, a colouring process or bleaching process.
- The protective action against UV radiation can be improved if the formulation comprises one or more UV filters.
- In principle, all UV filters are suitable for a combination. Particular preference is given to those UV filters whose physiological safety has already been demonstrated. There are many tried and tested substances known from the specialist literature both for UVA and also UVB filters, e.g.
- benzylidenecamphor derivatives, such as
- 3-(4′-methylbenzylidene)-dl-camphor (e.g. Eusolex® 6300),
- 3-benzylidenecamphor (e.g. Mexoryl® SD),
- polymers of N-{(2 and 4)-[(2-oxoborn-3-ylidene)methyl]benzyl}acrylamide (e.g. Mexoryl® SW),
- N,N,N,-trimethyl-4-(2-oxoborn-3-ylidenemethyl)anilinium methylsulphate (e.g. Mexoryl® SK) or
- α-(2-oxoborn-3-ylidene)toluene-4-sulfonic acid (e.g. Mexoryl® SL),
- benzoylmethanes or dibenzoylmethanes, such as
- -1-(4-tert-butylphenyl)-3-(4-methoxyphenyl)propane-1,3-dione (e.g. Eusolex® 9020) or
- -4-isopropyldibenzoylmethane, (e.g. Eusolex® 8020),
- benzophenones, such as
- 2-hydroxy-4-methoxybenzophenone (e.g. Eusolex® 4360) or
- 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and its sodium salt (e.g. Uvinul® MS-40),
- methoxycinnamic esters, such as
- octyl methoxycinnamate (e.g. Eusolex® 2292),
- isopentyl 4-methoxycinnamate, e.g. as a mixture of the isomers (e.g. Neo Heliopan® E 1000),
- salicylate derivatives, such as
- 2-ethylhexyl salicylate (e.g. Eusolex® OS),
- 4-isopropylbenzyl salicylate (e.g. Megasol®) or
- 3,3,5-trimethylcyclohexyl salicylate (e.g. Eusolex® HMS),
- 4-aminobenzoic acid and derivatives, such as
- 4-aminobenzoic acid,
- 2-ethylhexyl 4-(dimethylamino)benzoate (e.g. Eusolex® 6007),
- ethoxylated ethyl 4-aminobenzoate (e.g. Uvinul® P25),
- and further substances, such as
- 2-ethylhexyl 2-cyano-3,3-diphenylacrylate (e.g. Eusolex® OCR),
- 2-phenylbenzimidazole-5-sulphonic acid, and its potassium, sodium and triethanolamine salts (e.g. Eusolex® 232),
- 3,3′-(1,4-phenylenedimethylene)-bis(7,7-dimethyl-2-oxobicyclo-[2.2.1]hept-1-ylmethanesulphonic acid and salts thereof (e.g. Mexoryl® SX) and
- 2,4,6-trianilino(p-carbo-2′-ethylhexyl-1′-oxy)-1,3,5-triazine (e.g. Uvinul® T 150)
- 4,4-diaryl butadienes.
- The compounds given in the list are only to be regarded as examples. It is of course also possible to use other UV filters.
- These organic UV filters are usually incorporated into cosmetic formulations in an amount of from 0.5 to 10% by weight, preferably 1-8%.
- Examples of further suitable organic UV filters are
- 2-(2H-benzotriazol-2-yl)-4-methyl-6-(2-methyl-3-(1,3,3,3-tetramethyl-1-(trimethylsilyloxy)disiloxanyl)propyl)phenol (e.g. Silatriazole®),
- bis(2-ethylhexyl) 4,4′-[(6-[4-((1,1,-dimethylethyl)aminocarbonyl)phenylamino]-1,3,5-triazine-2,4-diyl)diimino]bis(benzoate) (e.g. Uvasorb® HEB),
- α-(trimethylsilyl)-ω-[(trimethylsilyl)oxy]poly[oxy(dimethyl [and approximately 6% methyl[2-[p-[2,2-bis(ethoxycarbonyl]vinyl]phenoxy]-1-methyleneethyl] and about 1.5% methyl[3-[p-2,2-bis(ethoxycarbonyl)vinyl)phenoxy)propenyl) and 0.1 to 0.4% (methylhydrogen)silylene]] (n≈60) (CAS No. 207 574-74-1),
- 2,2′-methylenebis(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol) (CAS No.103 597-45-1),
- 2,2′-(1,4-phenylene)bis (1H-benzimidazole-4,6-disulphonic acid, monosodium salt) (CAS No.180 898-37-7) and
- 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl )-1,3,5-triazine (CAS No.187 393-00-6).
- These organic UV filters are usually incorporated into cosmetic formulations in an amount of from 0.5 to 20% to 20% by weight, preferably 1-15%.
- Conceivable inorganic UV filters are those from the group of titanium dioxides, such as, for example, coated titanium dioxide (e.g. Eusolex® T-2000, Eusolex® T-AQUA), zinc oxides (e.g. Sachtotec®), iron oxides and also cerium oxides. These inorganic UV filters are usually incorporated into cosmetic formulations in an amount of from 0.5 to 20% by weight, preferably 2-10%.
- Preferred compounds with UV-filtering properties are 3-(4′-methylbenzylidene)-dl-camphor, 1-(4-tert-butylphenyl)-3-(4-methoxyphenyl)propane-1,3-dione, 4-isopropyldibenzoylmethane, 2-hydroxy-4-methoxy-benzophenone, octyl methoxy-cinnamate, 3,3,5-trimethylcyclohexyl salicylate, 2-ethylhexyl 4-(dimethylamino)-benzoate, 2-ethylhexyl 2-cyano-3,3-diphenylacrylate, 2-phenylbenzimidazole-5-sulphonic acid, and its potassium, sodium and triethanolamine salts.
- The organic or inorganic UV filters can be combined as desired with the compounds of the formula I. Based on the weight, the ratio of UV filters to the compounds of the formula I is preferably chosen between 1:10 and 10:1, in particular between 1:5 and 5:1.
- By combining one or more compounds of the formula I with further UV filters, the protective action against harmful effects of UV radiation can be optimized. The combination then demonstrates both a protective action as antioxidant and also against burns by UV radiation.
- The protecting action against oxidative stress or against the effect of free radicals can be further improved if the formulation comprises one or more further antioxidants.
- There are many tried and tested substances known from the specialist literature which can be used, e.g. amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and derivatives thereof, imidazoles (e.g. urocanic acid) and derivatives thereof, peptides, such as D,L-carnosine, D-carnosine, L-carnosine and derivatives thereof (e.g. anserine), carotenoids, carotenes (e.g. α-carotene, β-carotene, lycopene) and derivatives thereof, chlorogenic acid and derivatives thereof, lipoic acid and derivatives thereof (e.g. dihydrolipoic acid), aurothioglucose, propylthiouracil and other thiols (e.g. thioredoxin, glutathione, cysteine, cystine, cystamine and the glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, γ-linoleyl, cholesteryl and glyceryl esters thereof), and salts thereof, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and derivatives thereof (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts), and sulphoximine compounds (e.g. buthionine-sulphoximine, homocysteine-sulphoximine, buthionine-sulphones, penta-, hexa- and heptathionine-sulphoximine) in very low tolerated doses (e.g. pmol to pmol/kg), and also (metal) chelating agents, (e.g. α-hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), α-hydroxy acids (e.g. citric acid, lactic acid, malic acid), humic acid, bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and derivatives thereof, unsaturated fatty acids and derivatives thereof, vitamin C and derivatives (e.g. ascorbyl palmitate, magnesium ascorbyl phosphate, ascorbyl acetate), tocopherols and derivatives (e.g. vitamin E acetate), vitamin A and derivatives (e.g. vitamin A palmitate), and coniferyl benzoate of benzoin resin, rutinic acid and derivatives thereof, α-glycosyl rutin, ferulic acid, furfurylideneglucitol, carnosine, butylhydroxytoluene, butylhydroxyanisole, nordihydroguaiaretic acid, trihydroxy-butyrophenone, quercetin, uric acid and derivatives thereof, mannose and derivatives thereof, zinc and derivatives thereof (e.g. ZnO, ZnSO 4), selenium and derivatives thereof (e.g. selenomethionine), stilbenes and derivatives thereof (e.g. stilbene oxide, trans-stilbene oxide).
- Mixtures of antioxidants are likewise suitable for use in the cosmetic formulations according to the invention. Known and commercial mixtures are, for example, mixtures comprising, as active ingredients, lecithin, L-(+)-ascorbyl palmitate and citric acid (e.g. Oxynex® AP), natural tocopherols, L-(+)-ascorbyl palmitate, L-(+)-ascorbic acid and citric acid (e.g. Oxynex® K LIQUID), tocopherol extracts from natural sources, L-(+)-ascorbic acid and citric acid (e.g. Oxynex® L LIQUID), DL-α-tocopherol, citric acid and lecithin (e.g. Oxynex® LM) or butylhydroxytoluene (BHT), L-(+)-ascorbyl palmitate and citric acid (e.g. Oxynex® 2004).
- The antioxidants can be combined as desired with the compounds of the formula I. Based on the weight, the ratio of the antioxidant to the compounds of the formula I is preferably chosen between 1:10 and 10:1, in particular between 1:5 and 5:1.
- The formulations according to the invention can comprise vitamins as further ingredients. Preferably, vitamins and vitamin derivatives chosen from vitamin A, vitamin A propionate, vitamin A palmitate, vitamin A acetate, retinol, vitamin B, thiamine chloride hydrochloride (vitamin B 1), riboflavin (vitamin B2) nicotinamide, vitamin C (ascorbic acid), vitamin D, ergocalciferol (vitamin D2), vitamin E, DL-α-tocopherol, tocopherol E acetate, tocopherol hydrogensuccinate, vitamin K1, esculin (vitamin P active ingredient), thiamine (vitamin B1) nicotinic acid (niacin), pyridoxine, pyridoxal, pyridoxamine, (vitamin B6), pantothenic acid, biotin, folic acid and cobalamine (vitamin B12) are present in the cosmetic formulations according to the invention, particularly preferably vitamin A palmitate, vitamin C, DL-α-tocopherol, tocopherol E acetate, nicotinic acid, pantothenic acid and biotin.
- Furthermore, the formulation according to the invention may also comprise, as ingredient, ectoin (2-methyl-1,4,5,6-tetrahydropyrimidine-4-carboxylic acid) and in that case effects protection of the Langerhans cells. By adding 1-(2-hydroxyphenyl)alkan-1-one oxime, the formulation according to the invention develops an antiinflammatory action.
- The cosmetic or pharmaceutical formulation comprising at least one compound of the formula I is suitable particularly for protecting the body's cells against oxidative stress, in particular for reducing skin ageing.
- Also to be regarded as positive are the properties of compounds having the formula I for use in foodstuffs or as food supplements or as “functional food”. The explanations below given for foodstuffs also apply analogously to food supplements and to “functional food”.
- The foodstuffs which can be enriched according to the present invention with one or more compounds of the formula I include all materials which are suitable for consumption by animals or for consumption by humans, for example vitamins and provitamins thereof, fats, minerals or amino acids. (The foodstuffs may be solid, or else liquid, i.e. be in the form of a drink). Foodstuffs which can be enriched according to the present invention with one or more compounds of the formula I are, for example, also foodstuffs which originate from a single natural source, such as, for example, sugars, unsweetened juice, nectar or puree from a single plant species, such as, for example, unsweetened apple juice (e.g. also a mixture of different types of apple juice), grapefruit juice, orange juice, stewed apples, apricot nectar, tomato juice, tomato sauce, tomato puree, etc. Further examples of foodstuffs which can be enriched according to the present invention with one or more compounds of the formula I are corn or cereals of a single plant species and materials which are prepared from such plant species, such as, for example, cereal syrup, rye flour, wheatmeal or oat bran. Mixtures of such foodstuffs are also suitable for being enriched according to the present invention with one or more compounds of the formula I, for example multivitamin preparations, mineral substance mixtures or sugared juice. Further examples which may be mentioned of foodstuffs which can be enriched according to the present invention with one or more compounds of the formula I are foodstuff preparations, for example prepared cereals, bakery products, mixed drinks, foodstuffs prepared specifically for children, such as yoghurt, diet foodstuffs, low-calorie foodstuffs or animal feed.
- The foodstuffs which can be enriched according to the present invention with one or more compounds of the formula I thus include all palatable combinations of carbohydrates, lipids, proteins, inorganic elements, trace elements, vitamins, water or active metabolytes of plants and animals.
- The foodstuffs which can be enriched according to the present invention with one or more compounds of the formula I are preferably used orally, e.g. in the form of foods, pills, tablets, capsules, powders, syrup, solutions or suspensions.
- The foodstuffs according to the invention enriched with one or more compounds of the formula I can be prepared by techniques which are well known to the person skilled in the art.
- As a result of their advantageous action, in particular as antioxidants or as free-radical scavengers, compounds of the formula I are also suitable as medicaments. In this connection, they have a supporting or substituting action for natural mechanisms which scavenge free radicals within the body. With regard to their activity, the compounds of the formula I may sometimes be compared with free-radical scavengers such as vitamin C. Compounds of the formula I can be used, for example, for the preventative treatment of inflammation and allergies of the skin, and in certain cases for preventing certain types of cancer.
- Because of their antiallergic, antiinflammatory and antiirritative effects, compounds of the formula I are suitable in particular for the preparation of a medicament for the treatment of inflammations, allergies and irritations, in particular of the skin.
- In addition, it is possible to prepare medicaments which act as vein tonics, as agents for increasing the strength of blood capillaries, as inhibitants for cuperose, as inhibitors of chemical, physical or actinic erythemas, as agents for treating sensitive skin, as decongestants, as dehydrating agents, as weight-loss agents, as antiwrinkle agents, as stimulators of the synthesis of components of the extracellular matrix, as strengthening agents for improving elasticity of the skin and as anti-ageing agents.
- A further subject-matter of the invention relates to the stabilization of UV filters. A known and high-performance class of light protection filter substances is formed by the dibenzoylmethane derivatives. However, a disadvantage is that these substances are very readily decomposed by UV light and thus lose their protective properties. One example which may be mentioned of a commercially available light protection filter from this class of compound is 4-(tert-butyl)-4′-methoxydibenzoylmethane, which has the structure shown below.
- Surprisingly, it has now been found that compounds with the formula I have a very good stabilizing action for the dibenzoylmethanes, in particular 4-(tert-butyl)-4-methoxybenzoylmethane. A particularly high stabilizing action has been found for a compound of the formula I where X=—CH 2— and R1=R2=R3=R4=H. By incorporating mixtures of these compounds into cosmetics, it is now possible to prepare light protection compositions using dibenzoylmethanes which, even when subjected to prolonged periods of solar irradiation, for example during sunbathing for a number of hours, have no or only a very low reduction in the protective action against UV rays.
- The invention is illustrated in more detail using examples.
- Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
- The entire disclosures of all applications, patents and publications, cited above or below, and of corresponding German patent application No. 10056400.3, filed Nov. 14, 2000, are hereby incorporated by reference.
-
- A mixture of quercetin (604 mg, 2 mmol) and diphosphorus pentoxide (284 mg) in dichloromethane (10 ml) is heated to 75° C. Acetone (0.3 ml) is added dropwise to the suspension, and the mixture is stirred for a further hour at 75° C. Following removal of an oily residue, NaOH (25%, 1.5 ml) is added to the reaction mixture. The isolated organic phase is then washed with water and obtained by removal of the solvent under reduced pressure.
-
- a) Chlorination of 2-phenylbenzimidazole-5-sulphonic Acid:
- Dimethylformamide Chloride Synthesis:
- Equimolar amounts of thionyl chloride and DMFA are mixed with cooling. The mixture is left to stand for 30 min at room temperature and is then evaporated to constant weight at 30-40° C. with the exclusion of moisture in a water-jet vacuum. This gives a pale yellow-coloured crystal sludge which is washed with ether.
- Dimethylformamide chloride with 2-phenylbenzimidazole-5-sulphonic acid: 6.2 g of dimethylformamide chloride and 5 g of 2-phenylbenzimidazole-5-sulphonic acid are reacted in 120 ml of DMFA at 20° C. for 24 h. Ice is added to the mixture, which is then extracted with toluene. Following removal of the solvent, the desired product is obtained by recrystallization from CH 2Cl2/hexane.
- b) Reaction of 2-phenylbenzimidazole-5-sulphonyl Chloride with acetone-protected Quercetin:
- 2-phenylbenzimidazole-5-sulphonyl chloride (2 mol) and 3′,4′,7-tribenzylquercetin (1 mol) are refluxed in toluene. The organic phase is then washed with an aqueous solution of potassium carbonate. Following separation of the organic phase, the desired product is obtained by removing the solvent under reduced pressure.
-
- Iodine (0.1 mol) and diiodosilane (0.1 mol) are added to a solution of 2-ethylhexyl 4-(dimethylamino)benzoate (0.1 mol) in chloroform (5 ml). The reaction mixture is then stirred at 50° C. for 1.5 hours. Removal of the solvent gives 4-(dimethylamino)-2-acyliodide-benzene.
-
- a) Chlorination of 1-(4-tert-butylphenyl)-3-(4-methoxyphenyl)propane-1,3-dione (Eusolex 9020)
- 1-(4-tert-butylphenyl)-3-(4-methoxyphenyl)propane-1,3-dione (2.48 g) and acetyl chloride are added to a suspension of zinc (130 mg) in ether (20 ml) under protective gas, and the mixture is stirred for a further 1.5 hours. The reaction mixture is then quenched with water. After solid zinc has been removed by means of filtration, the reaction mixture is washed with ether (5×5 ml). The combined organic phases are washed with sodium carbonate and sodium chloride solution and dried under reduced pressure.
- b) Synthesis of the Ether:
- A mixture of 3′,4′,7-tribenzylquercetin (3 g), 1-(4-tert-butylphenyl)-3-(4-chlorophenyl)propane-1,3-dione and K 2CO3 (30 g) is refluxed in dried acetone (300 ml) for 21 hours. The solution is then suction-filtered, and washing is carried out a number times with warm acetone. The acetone is removed from the filtrate under reduced pressure to give the desired product.
- c) Deprotection:
- 3′,4′,7-tribenzyl-2-(1-(4-tert-butylphenyl)-3-(4-oxophenyl)propane-1,3-dione)quercetin is dissolved in 200 ml of methanol and hydrogenated using 0.3 g of 10% Pd/carbon at 1 bar. Removal of the catalyst and of the solvent used gives the desired product.
-
- 1 g of luteolin was introduced into 50 ml of pyridine and 50 ml of CH 2Cl2, and, at room temperature, 100 ml of cinnamyl chloride, dissolved in 25 ml of CH2Cl2, were slowly added dropwise. When the addition was complete, the mixture was stirred for a further 3 hours at room temperature. 100 ml of H2O and 50 ml of CH2Cl2 were then added, the organic phase was separated off and the aqueous phase was extracted with CH2Cl2. The combined organic phases were washed with water, 2N hydrochloric acid and aqueous sodium carbonate solution, and then dried. Following distillation of the solvent and recrystallization from toluene, fine white crystals were obtained.
- Yield: 2.16 g (83% of theory)
-
- 1 g of troxeluteolin and 50 ml of pyridine were introduced into 70 ml of CH 2Cl2. A solution of 10 ml of cinnamyl chloride in 50 ml of CH2Cl2 was then slowly added dropwise at room temperature. When the addition was complete, the reaction mixture was stirred for a further 3 hours. 50 ml of water were added, and the organic phase was separated off and washed with water, 2N hydrochloric acid and again with water and then aqueous calcium carbonate solution. The organic phase was dried and then the solvent was distilled off under reduced pressure. Recrystallization from toluene gave a pale beige powder.
- Yield: 1.09 g (67.3% of theory).
-
- 0.5 g of luteolin and 50 ml of pyridine were introduced into 25 ml of CH 2Cl2, and 1.026 g of trans-p-methoxycinnamyl chloride in 25 ml of CH2Cl2 was slowly added dropwise at room temperature. When the addition was complete, the reaction mixture was stirred for a further 8 hours. 100 ml of water and 200 ml of CH2Cl2 were added, the organic phase was separated off and the aqueous phase was extracted with CH2Cl2. The combined organic phases were washed with water, 2N hydrochloric acid and saturated sodium chloride solution.
- The solvent was distilled off under reduced pressure. Recrystallization from toluene gave a pale yellow powder.
- Yield: 0.48 g (39% of theory).
-
- 0.5 g of troxeluteolin and 25 ml of pyridine were introduced into 20 ml of CH 2Cl2 and then 0.9838 g of trans-methoxycinnamyl chloride in 20 ml of CH2Cl2 were slowly added dropwise at room temperature. When addition was complete, the mixture was stirred for a further 8 hours. 100 ml of H2O and 50 ml of CH2Cl2 were added, the organic phase was separated off and the aqueous phase was extracted with CH2Cl2. The combined organic phases were washed with water, 2N hydrochloric acid and again with water. Following drying, the solvent was distilled off under reduced pressure. Recrystallization from toluene gave a pale yellow powder.
- Yield: 0.63 g (59% of theory).
- Exemplary compositions of cosmetic formulations are given below.
- The compounds prepared in Examples 2 and 7 are used for the preparation of the compositions. Here, “compound 2” means the compound prepared in Example 2 and “compound 7” means the compound prepared in Example 7.
-
Care lotion (W/O) for application to the skin % by wt A Compound 7 1.00 Polyglyceryl-2 dipolyhydroxystearate 5.00 Beeswax 0.50 Zinc stearate 0.50 Hexyl laurate 9.00 Cetyl isononanoate 6.00 Shea butter 0.50 DL-α-Tocopherol acetate 1.00 B Glycerol 5.00 Magnesium sulphate heptahydrate 1.00 Preservative q.s. Water, demineralized ad 100.00 - Preparation:
- Phase A is heated to 75° C. and phase B is heated to 80° C. With stirring, phase B is slowly added to phase A. Following homogenization, the mixture is cooled with stirring. At a temperature of 40° C., perfume substances are added.
- The preservatives used are:
- 0.05% of propyl 4-hydroxybenzoate
- 0.15% of methyl 4-hydroxybenzoate
-
Care lotion (W/O) for application to the skin % by wt A Polyglyceryl-2 dipolyhydroxystearate 5.00 Beeswax 0.50 Zinc stearate 0.50 Hexyl laurate 9.00 Cetyl isononanoate 6.00 Shea butter 0.50 DL-α-Tocopherol acetate 1.00 B Compound 2 1.00 Glycerol 5.00 Magnesium sulphate heptahydrate 1.00 Preservative q.s. Water, demineralized ad 100.00 - Preparation:
- Phase A is heated to 75° C. and phase B is heated to 80° C. With stirring, phase B is slowly added to phase A. Following homogenization, the mixture is cooled with stirring. At a temperature of 40° C., perfume substances are added.
- The preservatives used are:
- 0.05% of propyl 4-hydroxybenzoate
- 0.15% of methyl 4-hydroxybenzoate
-
Skin cream (O/W) % by wt A Paraffin 2.00 Isohexadecane 2.00 Isopropyl palmitate 3.00 Soya oil 0.50 Dimethicone 1.00 Cetyl alcohol 1.00 Sorbitol stearate 1.50 Cetyl alcohol (and) cetyl glucoside 4.00 (−)-α-Bisabolol 0.30 B Water, demineralized ad 100.00 Compound 2 1.00 Glycerol 87% 10.00 D-Panthenol 0.50 (D+)-Biotin 0.05 Preservative q.s. C Xanthan gum 0.30 D Perfume 0.20 - Preparation:
- Phase A and phase B are heated separately to 75° C. Phase C is then slowly added to phase B and stirred until homogenized. The resulting B/C mixture is added to phase A at a temperature of 75° C., and the mixture is homogenized. Perfume substances are added after cooling to 35° C.
- The preservatives used are:
- 0.05% of propyl 4-hydroxybenzoate
- 0.15% of methyl 4-hydroxybenzoate
- 0.30% of Germall 115 (ISP, Frechen)
-
A Compound 7 1.00 Paraffin 2.00 Isohexadecane 2.00 Isopropyl palmitate 3.00 Soya oil 0.50 Dimethicone 1.00 Cetyl alcohol 1.00 Sorbitol stearate 1.50 Cetyl alcohol (and) cetyl glucoside 4.00 (−)-α-Bisabolol 0.30 B Water, demineralized ad 100.00 Glycerol 87% 10.00 D-Panthenol 0.50 (D+)-Biotin 0.05 Preservative q.s. C Xanthan gum 0.30 D Perfume 0.20 - Preparation:
- Phase A and phase B are heated separately to 75° C. Phase C is then slowly added to phase B and stirred until homogenized. The resulting B/C mixture is added to phase A at a temperature of 75° C. and the mixture is homogenized. After cooling to 35° C., perfume substances are added.
- The preservatives used are:
- 0.05% of propyl 4-hydroxybenzoate
- 0.15% of methyl 4-hydroxybenzoate
- 0.30% of Germall 115 (ISP, Frechen)
-
Sunscreen spray (O/W) % by wt A Compound 7 1.00 Eusolex ® 2292 (Art. No. 105382) 7.50 Eusolex ® HMS (Art. No. 111412) 7.00 Steareth-2 0.40 Steareth-10 0.80 Pemulen ® TR-2 1.18 Propylene glycol isoceteth-3 acetate 5.00 Performa ® V 825 0.80 Dimethicone 1.00 Oxynex ® K (Art. No. 108324) 0.10 B Eusolex ® 232 (Art. No. 105372) 1.00 Triethanolamine 0.90 1,2-propanediol 2.00 Preservative 0.50 Water, demineralized ad 100.00 - Preparation:
- Phase B:
- The water is mixed with the triethanolamine and then Eusolex® 232 is added with stirring. As soon as everything has dissolved, the further constituents of phase B are added and then the mixture is heated to 80° C.
- Phase A:
- The constituents of phase A, with the exception of Pemulen® TR-2, are combined and heated to 80° C. The Pemulen® TR-2 is then added with stirring.
- Preparation of the Sunscreen Composition:
- Phase B is slowly added with stirring to phase A. Following homogenization, the mixture is cooled with stirring.
- The preservatives used were:
- 0.05% of propyl 4-hydroxybenzoate
- 0.15% of methyl 4-hydroxybenzoate
-
Sunscreen spray (O/W) % by wt A Eusolex ® 2292 (Art. No. 105382) 7.50 Eusolex ® HMS (Art. No. 111412) 7.00 Steareth-2 0.40 Steareth-10 0.80 Pemulen ® TR-2 0.18 Propylene glycol isoceteth-3 acetate 5.00 Performa ® V 825 0.80 Dimethicone 1.00 Oxynex ® K (Art. No. 108324) 0.10 B Compound 2 1.00 Eusolex ® 232 (Art. No. 105372) 1.00 Triethanolamine 0.90 1,2-propanediol 2.00 Water, demineralized ad 100.00 - Preparation:
- Phase B:
- The water is mixed with the triethanolamine and then Eusolex® 232 is added with stirring. As soon as everything has dissolved, the further constituents of phase B are added and then the mixture is heated to 80° C.
- Phase A:
- The constituents of phase A, with the exception of Pemulen® TR-2, are combined and heated to 80° C. The Pemulen® TR-2 is then added with stirring.
- Preparation of the Sunscreen Composition:
- Phase B is slowly added to phase A with stirring. Following homogenization, the mixture is cooled with stirring.
- The preservatives used are:
- 0.05% of propyl 4-hydroxybenzoate
- 0.15% of methyl 4-hyrdoxybenzoate
-
Sunscreen gel (aqueous) % by wt A Compound 7 1.00 Eusolex ® 232 (Art. No. 105372) 4.00 Sodium hydroxide solution 6.00 Glycerol 3.00 1,2-propanediol 2.00 Preservative q.s. Water, demineralized ad 100.00 B Carbomer Ultrez-10 0.70 Water, demineralized 60.00 C Sodium hydroxide solution (10%) 1.50 Water, demineralized 4.00 - Preparation:
- Carbomer Ultrez-10 is completely dispersed in the water of phase B. Phase C is then slowly added and homogenized.
- For phase A, the water is firstly added to the sodium hydroxide solution and then the Eusolex® 232 is added and completely dissolved with stirring. After a clear solution has been obtained, the further constituents of phase A are added. Phase A is then added in portions to the mixture of phases B and C, the mixture being homogenized after each addition.
- The preservative used is:
- 0.20% of methyl 4-hydroxybenzoate
-
Sunscreen gel (O/W) % by wt A Compound 7 1.00 Eusolex ® 6300 (Art. No. 5385) 0.75 Luvitol ® EHO 10.00 Dimethicone 2.00 Shea butter 5.00 Antaron ® V-220 2.00 Oxynex ® K 1.00 B Eusolex ® 232 (Art. No. 5372) 0.75 Tris(hydroxymethyl)aminomethane 0.33 Preservative q.s. Water, demineralized 20.00 C Tris(hydroxymethyl)aminomethane 1.20 Water, demineralized 10.00 D Pemulen ® TR-1 0.60 Water, demineralized ad 100.00 - Preparation:
- The Pemulen® TR-1 is dissolved in the water of phase D. The tris(hydroxymethyl)aminomethane is dissolved in the water of phase C and the solution is added to phase D. The tris(hydroxymethyl)aminomethane is dissolved in the water of phase B and then the Eusolex® 232 is added with stirring. After an aqueous solution has been obtained, the further constituents of phase B are added and then phase B is added to the mixture of phases C and D and homogenized. The constituents of phase A are combined and heated. Phase A is then added to the mixture of the other phases with homogenization.
- The preservatives used are:
- 0.05% of propyl 4-hydroxybenzoate
- 0.15% of methyl 4-hydroxybenzoate
-
Sunscreen gel (O/W) % by wt A Eusolex ® 6300 (Art. No. 5385) 0.75 Luvitol ® EHO 10.00 Dimethicone 2.00 Shea butter 5.00 Antaron ® V-220 2.00 Oxynex ® K liquid (Art. No. 8324) 1.00 B Compound 2 1.00 Eusolex ® 232 (Art. No. 5372) 0.75 Tris(hydroxymethyl)aminomethane 0.33 Preservative q.s. Water, demineralized 20.00 C Tris(hydroxymethyl)aminomethane 1.20 Water, demineralized 10.00 D Pemulen ® TR-1 0.60 Water, demineralized ad 100.00 - Preparation:
- The Pemulen® TR-1 is dissolved in the water of phase D. The tris(hydroxymethyl)aminomethane is dissolved in the water of phase C and the solution is added to phase D. The tris(hydroxymethyl)aminomethane is dissolved in the water of phase B and then the Eusolex® 232 is added with stirring. After a clear solution has been obtained, the further constituents of phase B are added and then phase B is added to the mixture of phases C and D and homogenized. The constituents of phase A are combined and heated. Phase A is then added to the mixture of the other phases with homogenization.
- The preservatives used are:
- 0.05% of propyl 4-hydroxybenzoate
- 0.15% of methyl 4-hydroxybenzoate
-
Sunscreen lotion (W/O) with UVA/B protection % by wt A Compound 7 1.00 Eusolex ® 2292 (Art. No. 1.05382) 3.00 Eusolex ® 4360 (Art. No. 1.05376) 2.00 Dehymuls ® E 6.00 Hydrogenated castor oil 1.00 Beeswax 2.00 Oleyl erucate 6.00 Decyl oleate 6.00 Dicapryl ether 5.00 Dimethicone 1.00 B Glycerol (87%) 5.00 Magnesium sulphate heptahydrate 1.00 Preservative q.s. Water, demineralized ad 100.00 - Preparation:
- The constituents of phases A and B are mixed in each case. Phase A is heated to 75° C. and phase B is heated separately to 80° C. Phase B is added to phase A with homogenization. The mixture is then cooled with stirring.
- The preservatives used are:
- 0.05% of propyl 4-hydroxybenzoate
- 0.15% of methyl 4-hydroxybenzoate
-
Sunscreen lotion (W/O) with UVA/B protection % by wt A Eusolex ® 2292 (Art. No. 1.05382) 3.00 Eusolex ® 4360 (Art. No. 1.05376) 2.00 Dehymuls ® E 6.00 Hydrogenated castor oil 1.00 Beeswax 2.00 Oleyl erucate 6.00 Decyl oleate 6.00 Dicapryl ether 5.00 Dimethicone 1.00 B Compound 2 1.00 Glycerol (87%) 5.00 Magnesium sulphate heptahydrate 1.00 Preservative q.s. Water, demineralized ad 100.00 - Preparation:
- The constituents of phases A and B are mixed in each case. Phase A is heated to 75° C. and phase B is heated separately to 80° C. Phase B is added to phase A with homogenization. The mixture is then cooled with stirring.
- The preservatives used are:
- 0.05% of propyl 4-hydroxybenzoate
- 0.15% of methyl 4-hydroxybenzoate
- The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.
- From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.
Claims (20)
1. A compounds of the formula I
where
X is O, S or NH;
Y is O, S or NH;
a single or double bond may be provided between carbons C-2 and C-3,
R1 and R2, and R3 and R4 may be provided at any positions on the ring, and also
R1, R2, R3, R4 and R5 may be identical or different and independently of one another are —H, —OH or —OA, and
A is a group which absorbs UV radiation selected from the group formed from:
and at least one of the groups R1, R2, R3, R4 or R5 is formed by —OA.
2. A compound of formula I
where
X is O, S or NH;
Y is O, S or NH;
a single or double bond may be provided between carbons C-2 and C-3,
R1 and R2, and R3 and R4 may be provided at any positions on the ring, and also
R1, R2, R3, R4 and R5 may be identical or different and independently of one another are —H, —OH or —OA,
in addition R1, R2, R3, R4 and R5, independently of one another, can stand for a
straight-chain or branched oxyalkyl or carboxyalkyl group having 1 to 12 carbon atoms,
straight-chain or branched oxyalkenyl or carboxyalkenyl group having 2 to 12 carbon atoms,
straight-chain or branched hydroxyoxyalkyl group having 1 to 12 carbon atoms, where the hydroxyl group may be bonded to a primary or secondary carbon atom and, furthermore, the alkyl chain can also be interrupted by oxygen,
sulphate group,
phosphate group
and a mono- or oligoglycosyl radical, and
A is a group which absorbs UV radiation selected from the group formed from:
and at least one of the groups R1, R2, R3, R4 or R5 is formed by —OA.
5. In a cosmetic or pharmaceutical formulation comprising an active ingredient and a physiologically acceptable carrier, the improvement wherein said formulation comprises at least one compound according to claim 1 .
6. In a cosmetic or pharmaceutical formulation comprising an active ingredient and a physiologically acceptable carrier, the improvement wherein said formulation comprises at least one compound according to claim 2 .
7. In a cosmetic or pharmaceutical formulation comprising an active ingredient and a physiologically acceptable carrier, the improvement wherein said formulation comprises at least one compound according to claim 3 .
8. In a cosmetic or pharmaceutical formulation comprising an active ingredient and a physiologically acceptable carrier, the improvement wherein said formulation comprises at least one compound according to claim 4 .
9. A cosmetic formulation according to claim 5 , where the formulation comprises one or more additional UV filters and/or antioxidants.
10. A cosmetic formulation according to claim 6 , where the formulation comprises one or more additional UV filters and/or antioxidants.
11. A method for protecting the body's cells of a patient against oxidative stress, in particular for reducing skin ageing, comprising administering to said patient a formulation according to claim 5 .
12. A method for protecting the body's cells of a patient against oxidative stress, in particular for reducing skin ageing, comprising administering to said patient a formulation according to claim 6 .
13. An enriched foodstuff comprising a foodstuff and at least one compound according to claim 1 .
14. An enriched foodstuff comprising a foodstuff and at least one compound according to claim 2 .
15. A compound according to claim 1 as medicaments.
16. A compound according to claim 2 as medicaments.
17. Use of a compound according to claim 2 for the preparation of a medicament against oxidative stress, in particular for reducing skin ageing.
18. Use of a compound according to claim 2 for the preparation of a medicament for the treatment of inflammations or allergic reactions.
19. Use of a compound according to claim 2 as antioxidant, in particular for cosmetic formulations.
20. Use of compounds according to claim 2 for the stabilization of UV filters, in particular dibenzoylmethane and derivatives of dibenzoylmethane.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/833,137 US7345090B2 (en) | 2000-11-14 | 2004-04-28 | Galenical formulation |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10056400A DE10056400A1 (en) | 2000-11-14 | 2000-11-14 | Galenic formulation |
| DE10056400.3 | 2000-11-14 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/833,137 Continuation US7345090B2 (en) | 2000-11-14 | 2004-04-28 | Galenical formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20020106338A1 true US20020106338A1 (en) | 2002-08-08 |
Family
ID=7663259
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/987,439 Abandoned US20020106338A1 (en) | 2000-11-14 | 2001-11-14 | Galenical formulation |
| US10/833,137 Expired - Fee Related US7345090B2 (en) | 2000-11-14 | 2004-04-28 | Galenical formulation |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/833,137 Expired - Fee Related US7345090B2 (en) | 2000-11-14 | 2004-04-28 | Galenical formulation |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20020106338A1 (en) |
| EP (1) | EP1205475B1 (en) |
| JP (1) | JP2002193962A (en) |
| AT (1) | ATE280764T1 (en) |
| DE (2) | DE10056400A1 (en) |
| ES (1) | ES2230224T3 (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060111308A1 (en) * | 2004-11-16 | 2006-05-25 | Wendye Robbins | Methods and compositions for therapeutic treatment |
| US20070087977A1 (en) * | 2004-11-16 | 2007-04-19 | Wendye Robbins | Methods and compositions for treating pain |
| US20070184098A1 (en) * | 2003-06-20 | 2007-08-09 | Philippe Moussou | Esters of flavonoids with w-substituted c6-c22 fatty acids |
| US20070264205A1 (en) * | 2004-12-21 | 2007-11-15 | Avon Products Inc. | Cosmetic compositions having carnitine creatinate and methods for using |
| WO2007082178A3 (en) * | 2006-01-06 | 2008-03-27 | Abgenomics Corp | Prostaglandin reductase inhibitors |
| WO2009018350A1 (en) * | 2007-07-31 | 2009-02-05 | Limerick Biopharma, Inc. | Pyrone analog compositions and methods |
| US20090069273A1 (en) * | 2007-07-31 | 2009-03-12 | Wendye Robbins | Phosphorylated pyrone analogs and methods |
| US20090215881A1 (en) * | 2005-06-17 | 2009-08-27 | Rhodia Chime CHIMIE | Polyphenolic Bioprecursors |
| EP2468741A1 (en) | 2010-12-16 | 2012-06-27 | Bel/Novamann International s.r.o. | Novel quercetin derivatives, their preparation, pharmaceutical compositions containing them and their use |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10244282A1 (en) * | 2002-09-23 | 2004-04-01 | Merck Patent Gmbh | Preparation with antioxidant properties |
| FR2857665B1 (en) * | 2003-07-16 | 2006-02-10 | Centre Nat Rech Scient | NOVEL FLAVON DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
| WO2005074959A1 (en) | 2004-02-05 | 2005-08-18 | Access Business Group International Llc | Anti-allergy composition and related method |
| US8017649B2 (en) * | 2005-03-11 | 2011-09-13 | Howard Florey Institute Of Experimental Physiology And Medicine | Flavonoid compounds and uses thereof |
| FR2888112B1 (en) * | 2005-07-11 | 2008-02-22 | Oreal | PHOTOPROTECTIVE COMPOSITION COMPRISING AN AQUEOUS PHASE AND A LOW MELT POOL APOLAR WAX |
| US20070009453A1 (en) * | 2005-07-11 | 2007-01-11 | L'oreal | Photoprotective compositions comprising an aqueous phase and a low melting point apolar wax |
| CL2008003651A1 (en) | 2007-12-10 | 2009-06-19 | Novartis Ag | Substituted 3,5-diamino-6-chloropyrazinamide derivative compounds; pharmaceutical composition; pharmaceutical combination; and use in the treatment of an inflammatory or allergic condition, in particular an inflammatory or obstructive disease of the airways. |
| FR2936706B1 (en) * | 2008-10-08 | 2010-12-17 | Oreal | COSMETIC COMPOSITION CONTAINING A DIBENZOYLMETHANE DERIVATIVE AND A DITHIOLANE COMPOUND; METHOD FOR PHOTOSTABILIZATION OF THE DIBENZOYLMETHANE DERIVATIVE |
| US8372820B2 (en) * | 2009-04-15 | 2013-02-12 | Conopco, Inc. | Composition comprising silicone oil or oils structured with compolymers carrying greater than 70% long chain alkyl group |
| US9138390B2 (en) * | 2009-04-15 | 2015-09-22 | Conopco, Inc. | Petrolatum based composition comprising greater than 10% silicone for improved feel while remaining stable |
| US20110098311A1 (en) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorported | Compositions for treatment of cystic fibrosis and other chronic diseases |
| JP5604161B2 (en) * | 2010-04-12 | 2014-10-08 | 株式会社ファンケル | Sunscreen cosmetics |
| CA2996064C (en) * | 2015-08-18 | 2024-02-13 | Novation Pharmaceuticals Inc. | Benzopyran derivatives and uses thereof |
| CN110642825B (en) * | 2019-10-16 | 2021-06-15 | 中国海洋大学 | A kind of flavonoid derivative, its preparation method and application in preparing immune enhancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2687572B1 (en) * | 1992-02-26 | 1995-06-09 | Oreal | USE OF CERTAIN FLAVONOUIDS IN COSMETIC COMPOSITIONS, AND METHOD FOR PROTECTING THE SKIN, ITS PHANERES AND COSMETIC COMPOSITIONS. |
| FR2708851B1 (en) | 1993-08-12 | 1995-09-22 | Oreal | Cosmetic composition comprising the combination of a nanopigment of metal oxides and an antioxidant, and its use for the protection of the skin and hair. |
| DE19508608B4 (en) * | 1994-03-23 | 2006-06-29 | Merck Patent Gmbh | Light-resistant cosmetic agent containing tetraalkylquercetin and Tetraalkylquercetine as such |
| DE4444238A1 (en) * | 1994-12-13 | 1996-06-20 | Beiersdorf Ag | Cosmetic or dermatological drug combinations of cinnamic acid derivatives and flavone glycosides |
| US5665367A (en) * | 1996-09-27 | 1997-09-09 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Skin care compositions containing naringenin and/or quercetin and a retinoid |
-
2000
- 2000-11-14 DE DE10056400A patent/DE10056400A1/en not_active Withdrawn
-
2001
- 2001-11-13 JP JP2001347280A patent/JP2002193962A/en active Pending
- 2001-11-14 EP EP01126541A patent/EP1205475B1/en not_active Expired - Lifetime
- 2001-11-14 US US09/987,439 patent/US20020106338A1/en not_active Abandoned
- 2001-11-14 AT AT01126541T patent/ATE280764T1/en not_active IP Right Cessation
- 2001-11-14 DE DE50104283T patent/DE50104283D1/en not_active Expired - Lifetime
- 2001-11-14 ES ES01126541T patent/ES2230224T3/en not_active Expired - Lifetime
-
2004
- 2004-04-28 US US10/833,137 patent/US7345090B2/en not_active Expired - Fee Related
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070184098A1 (en) * | 2003-06-20 | 2007-08-09 | Philippe Moussou | Esters of flavonoids with w-substituted c6-c22 fatty acids |
| US20090088394A1 (en) * | 2004-11-16 | 2009-04-02 | Wendye Robbins | Methods and compositions for therapeutic treatment |
| US20070087977A1 (en) * | 2004-11-16 | 2007-04-19 | Wendye Robbins | Methods and compositions for treating pain |
| US20060111308A1 (en) * | 2004-11-16 | 2006-05-25 | Wendye Robbins | Methods and compositions for therapeutic treatment |
| US20090076053A1 (en) * | 2004-11-16 | 2009-03-19 | Wendye Robbins | Methods and compositions for treating pain |
| US20070264205A1 (en) * | 2004-12-21 | 2007-11-15 | Avon Products Inc. | Cosmetic compositions having carnitine creatinate and methods for using |
| US9067908B2 (en) * | 2005-06-17 | 2015-06-30 | Rhodia Chimie | Polyphenolic bioprecursors |
| US20090215881A1 (en) * | 2005-06-17 | 2009-08-27 | Rhodia Chime CHIMIE | Polyphenolic Bioprecursors |
| WO2007082178A3 (en) * | 2006-01-06 | 2008-03-27 | Abgenomics Corp | Prostaglandin reductase inhibitors |
| US20090124688A1 (en) * | 2006-01-06 | 2009-05-14 | Rong-Hwa Lin | Prostaglandin reductase inhibitors |
| US20090069273A1 (en) * | 2007-07-31 | 2009-03-12 | Wendye Robbins | Phosphorylated pyrone analogs and methods |
| US20090258939A1 (en) * | 2007-07-31 | 2009-10-15 | Wendye Robbins | Pyrone analog compositions and methods |
| US20100144612A1 (en) * | 2007-07-31 | 2010-06-10 | Limerick Biopharma, Inc. | Phosphorylated pyrone analogs and methods |
| US20100204089A1 (en) * | 2007-07-31 | 2010-08-12 | Limerick Biopharma, Inc. | Phosphorylated pyrone analogs and methods |
| US7947733B2 (en) | 2007-07-31 | 2011-05-24 | Limerick Biopharma | Phosphorylated pyrone analogs and methods |
| WO2009018350A1 (en) * | 2007-07-31 | 2009-02-05 | Limerick Biopharma, Inc. | Pyrone analog compositions and methods |
| EP2468741A1 (en) | 2010-12-16 | 2012-06-27 | Bel/Novamann International s.r.o. | Novel quercetin derivatives, their preparation, pharmaceutical compositions containing them and their use |
Also Published As
| Publication number | Publication date |
|---|---|
| DE50104283D1 (en) | 2004-12-02 |
| ES2230224T3 (en) | 2005-05-01 |
| DE10056400A1 (en) | 2002-05-23 |
| EP1205475B1 (en) | 2004-10-27 |
| JP2002193962A (en) | 2002-07-10 |
| US20040202624A1 (en) | 2004-10-14 |
| EP1205475A1 (en) | 2002-05-15 |
| ATE280764T1 (en) | 2004-11-15 |
| US7345090B2 (en) | 2008-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7345090B2 (en) | Galenical formulation | |
| US6538021B1 (en) | Method for producing luteolin and luteolin derivatives | |
| JP4504619B2 (en) | Cosmetic preparation | |
| JP4850397B2 (en) | Use of chromen-4-one derivatives | |
| RU2454394C2 (en) | Antioxidants | |
| EP1251818B9 (en) | Galenic formulation | |
| EP1250331B1 (en) | Formulation for protection against oxidative stress containing benzofuranone derivatives | |
| JP2004115513A (en) | Preparations with antioxidant properties | |
| JP2004051637A (en) | Photoprotectant | |
| JP2005132842A (en) | Composition having antioxidation property | |
| US7588783B2 (en) | Flavonoid derivative | |
| CA2348728A1 (en) | Method for the production of quercetin and isoquercetin derivatives | |
| JP2007502787A (en) | Chromen-4-one derivatives | |
| CN1938289A (en) | Chromone complexes | |
| JP2008520597A (en) | Compositions containing oxidized flavonoid derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: MERCK PATENT GESELLSCHAFT, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PFLUECKER, FRANK;BUENGER, JOACHIM;DRILLER, HANS-JUERGEN;AND OTHERS;REEL/FRAME:012575/0645 Effective date: 20020128 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |




















